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1.0  MOLECULAR IMAGING 
 
“Imaging” refers to the generic process through which it is possible to observe an 
area of a living organism not visible from the outside and it is widely employed in 
clinical diagnostics in order to detect and locate physiological and pathological 
phenomena.  
In "vivo" medical imaging has made wide improvement through advances in the 
engineering of imaging devices and developments in the chemistry of probes. Over 
the past years, the National Cancer Institute recognized Molecular Imaging as an 





Molecular imaging is a scientific discipline and it is a result of combined advances 
in chemistry, biology, physics and engineering. It can be defined as the 
visualization, characterization, and measurement of biological processes at the 
molecular and cellular levels in humans and other living systems and molecular 
imaging agents are probes used to visualize, characterize, and measure biological 
processes. These two definitions were stated by the Society of Nuclear Medicine in 





Molecular imaging employs contrast agents or probes of different nature to gain 
more information. The advantages of using more specific molecular probes are 
evident for personalized medicine and for accelerating the time and the quality of 






1.1 BASIC PRINCIPLES OF IMAGING MODALITIES: BASIC OF 
DIAGNOSTIC IMAGING TECHNIQUES 
 
Imaging modalities can be simply divided into two categories: 
 
 Morphological and anatomical techniques including Computed 
Tomography (CT), Magnetic Resonance Imaging (MRI) and Ultrasound 
Sonography (US). They are characterized by high spatial resolution but they 
are not able to give any information about little changes at the tissue or cell 
levels. As a matter of fact, these techniques are able to give images of the 
body that allow to detect coarse changes in a tissue such as tumours in 
advanced stages. 
 Molecular Imaging techniques include Single Photon Emission Computed 
Tomography (SPECT), Positron Emission Tomography (PET), Optical 
Imaging (OI) and Photoacoustic Tomography (PAT). Thanks to the use of 
radiopharmaceuticals, luminophores and choromophores injected at 
nanomolar blood concentration they allow to detect subtle changes inside a 
tissue in a pathological situation (for example early stage tumours). 
Unfortunately nuclear techniques as SPECT and PET do not possess a great 
spatial resolution and Optical Imaging techniques suffer from a limited 
tissue penetration. 
Combining morphological/anatomical and molecular imaging modalities, it is 
possible to obtain a better imaging of the pathophysiological changes in early 














Strengths Weaknesses Cost Throughput 
Sensitivity 
([M] of label 
detected) 
Resolution 
CT None X-rays Fast, cross-sectional images 
Poor resolution of soft 
tissues 
High Low 10-6 50µm 
MRI 




Harmless, high-resolution of 
soft tissues 
Cannot follow many 
labels 
High Low 10-9-10-6 50µm 
US 
Microbubbles, which can 
be combined with targeted 
contrast agents 
 
Sound waves Quick, harmless Poor image contrast Low High 10-8 50µm 
SPECT Radiolabelled molecules γ-rays 
Can distinguish between 
radionuclides, so more 
processes can be imaged at 
once 
Requires radioactivity High Low 10-14 1-2mm 
PET Radiolabelled molecules 




Can detect only one 
radionuclide, implies 
radioactivity 
High Low 10-15 1-2mm 
OI 
Genetically engineered 






technique readily adapted to 
study specific molecular 
events 
Poor depth penetration Low High 10-12 50µm 
PAT 
Probes that absorb light 
and create sound signals 
Sound waves 
Better depth resolution than 
light 
Information processing 
and machines still being 
optimized 




1.1.1 Computed Tomography 
Computed tomography (CT) was introduced in the clinical practice in 1972 and 
rapidly became a very important tool in the radiological diagnosis. For example CT 
of the brain became the procedure of choice for evaluation of brain tumours. It 
replaced invasive procedures such as pneumoencephalography and the progressive 
improvement of the image quality, reduction of costs, and reduction of scan times 
has resulted in significant expansion of CT applications.
[4] 
CT  is a medical imaging 
method that combines multiple X-ray projections taken from different angles to 
produce detailed cross-sectional images of areas inside the body. CT images allow 
to obtain very precise 3D views of certain parts of the body, such as soft tissues, 
blood vessels, lungs, brain, heart, abdomen, pelvis and bones. It is often used to 
locate bone and traumatic injuries, vascular condition/blood flow, abdominal aortic 
aneurysms, pulmonary embolism, cardiovascular disease and to measure the size 
and location of tumours. 
 









1.1.2 Magnetic Resonance Imaging 
 
Magnetic resonance imaging (MRI) is a medical imaging technique commonly 
used to visualize structures and functions of the body providing detailed images in 
any plane using intravenous contrast agent.
[6]
 
This technique is based on the principles of nuclear magnetic resonance. A 
powerful magnetic field aligns the nuclear magnetization of hydrogen atoms of the 
body water molecules. Radio frequency (RF) fields are used to systematically alter 
the alignment of this magnetization inducing the hydrogen nuclei to produce a 




Figure 2. Schematic illustration of MRI: a mouse is placed inside a magnet. Unpaired nuclear spin within the 
body either align parallel or anti-parallel with the direction of the magnetic field. MR signal is generated from a 
very small difference in number of parallel versus anti-parallel spins. MRI images with or without contrast 
agents are reported. [5] 
 
1.1.3 Ultrasound Sonography 
 
Ultrasound (US) imaging is based on the use of the sound at frequency higher than 
20 KHz to obtain projections of the organism. Ultrasound contrast agents (UCAs) 
can be used to improve US-imaging and are based on materials characterized by 
different acoustic properties respect to other tissues. The most common approach is 




improve the Doppler signal from blood vessels. One of its most important 





Figure 3. Schematic illustrating the general principles of molecular imaging using US. US images 
demonstrating the significant advantage of using microbubbles targeted to vascular endothelial growth factor 
receptor type 2 (VEGFR2) compared with non-targeted microbubbles for visualizing tumour angiogenesis in 
mice. [5] 
 
1.1.4 Single Photon Emission Computed Tomography 
 
Single Photon Emission Computed Tomography (SPECT) is a medical imaging 
technique commonly used to obtain 3D biotopological data of the body. SPECT 
use -rays to collect images through a gamma-camera that provides a series of two-
dimensional views of the distribution in the body of a radionuclide previously 
administered to the patient.  The radionuclide may be introduced into the patient, 






Figure 4. SPECT principles. The radiotracer previously administrated to the patient decay emitting photons. 
Produced photons transfer energy to the gamma-camera detector. Because photons are emitted in all directions, 
a collimator is used to collect only photons that are travelling perpendicular to the detector surface. These 
detectors are made of a high density material, such as lead or steel, through which there are multiple parallel 
holes. To collect a tomographic image, the gamma camera rotates around the body, collecting a set of 
overlapping planar images that are elaborated through a 'back projection' technique.  
 
1.1.5 Positron Emission Tomography 
 
Positron Emission Tomography (PET) is one of the most recent techniques used in 
medical diagnostics and it is able to give functional imaging of the body. This 
technique exploits positrons issued following radioactive decay of the previously 
administered tracer. PET is very useful to locate functional changes inside an organ 
or an entire apparatus and it is essential for early diagnosis. In fact, physiological 









Figure 5. PET scanners detect  the simultaneous outcoming of two photons of a characteristic 
energy from opposed detectors (lower panels), a process is termed 'coincidence'. The photons have 
an energy of 511 keV, which is the energy released from an electron-positron annihilation reaction. 
A tomographic image is obtained by combining many 'lines of coincidence'. 
 
1.1.6 Optical Imaging  
 
Optical imaging uses light to visualize the body, and so it is sensitive to compounds 
and structures in tissues that are able to provide optical contrast. The acquired 
image depends on the light wavelength applied and the instrumental mode of 
detection. Generally, light tissue interaction is characterized by the processes of 
absorption, photon scattering and fluorescence emission. Optical contrast 
mechanisms include absorption, fluorescence, luminescence and scattering. Optical 
imaging combines different modalities with a great potential for biomedical 
imaging. These techniques are used in molecular imaging to visualize and quantify 
altered molecular mechanism in a non-invasive and ionising radiation-free manner, 









Figure 6. General principles of molecular imaging using optical fluorescence [5] 
 
1.1.7 Photoacoustic Tomography 
 
First reported by Alexander Graham Bell in 1880 
[11]
, the photoacoustic effect can 
be exploited for imaging purposes. It can be described as the production of sound 
waves resulting from the absorption of light. One of the main advantages of PAT is 
its depth of penetration (from 6 mm to 5 cm), which is superior to that of most 
optical techniques. In addition, the spatial resolution of PAT is not negatively 
influenced by increases in depth of penetration, as is typically the situation with 
other optical modalities and US. 
 




1.2  OPTICAL IMAGING  
 
 
Optical Imaging is a light-based technology with a great potential to improve the in 
vivo and in vitro diagnosis and treatment of various diseases. It offers a number of 
important advantages over existing radiological imaging techniques using non-
ionising radiation. Moreover, the use of dedicated “probes” offers the possibility to 
study selected biological pathways at the functional and molecular level in a living 




Figure 8. Optical Imaging principles 
 
The principles underlying selected techniques of molecular imaging are shown in 
Figure 8. The target is irradiated by a high intensity light source, usually a laser. 
The image can be obtained by detecting the luminescence of suitable fluorescent 
agents (fluorescence imaging), previously administered. In a different technique 




detected, arising from the sound waves resulting by the local expression following 
the absorption of radiation by selected probes. In both imaging techniques, the 
molecular probe must be endowed with a strong ability to absorb the radiation of 
the source. Laser sources in the red and infrared region are preferred due to their 
significant penetration depth in tissues. In fluorescence imaging, the molecular 
probe must receive the absorbed energy in the form of a longer-wavelength 
radiation. In PAT, the molecular probe must undergo to a nonradiative decay, 
releasing thermal energy leading to adiabatic expansion of the local environment. 
 
1.2.1 General requirement for fluorescent probes in Optical Imaging 
 
A successful optical molecular probe for medical imaging should have several 
adjective properties such as brightness, bio- and photostability, and specific 




 WAVELENGTH: fluorophores require excitation light to emit a signal. 
Excitation in the ultraviolet cannot be used because may cause direct tissue 
damage,
[13]
 blue or green excitation light have poor tissue penetration and 
fluorophores which need excitation with about 600 nm (yellow light) are 
not applicable due to the presence of endogenous molecules responding at 
the same wavelength. In fact the tissue autofluorescence at these 
wavelengths could be too high to be distinguished from the exogenous 
fluorophore signal.
[14]
 The best excitation wavelength of a fluorophore is 
between near-infrared and the deep red range due to a good tissue 






Figure 9. Electromagnetic spectrum 
 
 BRIGHTNESS: of course, the brighter the agent, better will be signal-to-
noise ratio. To be able to increase the brightness, the size of the fluorophore 
must be larger. However, in this situation different problems ensues such as 
a difficult conjugation and higher toxicity.
[12]
 
 STABILITY: the in vivo stability is another crucial point. Once internalized 
into the lysosome, most of the fluorophores, such as fluorescein, BODIPY, 
and cyanine derivatives except rhodamines, lose fluorescence in several 
days. Rhodamine is an exception because it can keep fluorescence for 
longer than a week. 
[16-17]
 Furthermore, photodegradation is a very usual 
phenomenon for this type of molecules. Although the stability is essential 
some level of degradation is desirable so that the product could be easily 
conjugated, metabolized and  excreted.  
 PHARMACOKINETICS: fluorophores are often conjugated with 
biomolecules such as proteins, sugars and antibodies. Most of small-
molecules fluorophores may alter the pharmacokinetics of targeting 
portions to which they are conjugated. Pharmacokinetic and toxicological 
studies are vital to understand biological half-life, specific tissue 





1.2.2  Classification 
 
Fluorophores can be divided into three major classes: 
 
 SMALL-MOLECULE FLUOROPHORES: are synthetic fluorophores with 
various core structures including fluorescein, BODIPY, rhodamine, and 
cyanine derivatives. All of these are commercial available, with molecular 
ranges between 300 to 2000 Da and cover the emission spectrum from blue 
to NIR.
[18] 
 GENETICALLY ENCODED FLUORESCENT PROTEINS: they are 
artificial proteins with emission wavelengths not found in nature, including 
infrared. 
[19]
  In particular three proteins can be cited including green 
fluorescent protein (GFP), yellow fluorescent protein (YFP), and red 
fluorescent protein (RFP). Some of them have unique features among which 
a large Stokes shift.
[20]
 
 NANOCRYSTALS: are synthetic materials characterised by a broad 
excitation range, a narrow emission peak, resistance to photodegradation, 
and extremely high brightness.
[21]
 Numerous nanocrystals with unique 
optical properties have been reported. They are new products belonging to 
the field of nanotechnologies, however the pharmacokinetic and 
pharmacodynamic will be investigated together with many toxicological 
studies to report any shadows about their use. 
 
1.2.3  Small-Molecule Fluorophores 
 
 Fluorescein is a synthetic organic compound soluble in water and alcohol. It 
is widely employed as a fluorescent tracer for many optical applications. 











Figure 13. Fluorescein structure 
 




 BODIPY dyes have been described for the first time in 1968 by Treibs and 
Kreuzer.
[23]
 BODIPY dyes are notable for their uniquely Stokes shift, high 
fluorescence quantum yields and high solubility in many organic solvents. 
The combination of these qualities makes BODIPY fluorophore an 
important tool in a variety of imaging applications. With derivatives that 
span the entire visible spectrum BODIPY dyes are proving to be extremely 
versatile. Some of these compounds have very excellent spectral 
characteristics and they are largely better than fluorescein. 
[24]
 They are used 
for in vitro clinical diagnostics or biological, pharmacological and 
biochemistry research. Most of these dyes are used to generate fluorescent 
conjugates such as enzymes, fatty acids, phospholipids, lipopolysaccharides 
and receptor ligands. In addition, oligonucleotide conjugates BODIPY dyes 
have been reported to be useful for DNA sequencing,
[25,26,27]
 nucleic acid 
hybridization 
[28]








Figure 10. The structure and numbering of the BODIPY fluorophore, 4,4-difluoro-4-bora-3a,4a-diaza-s-
indacene is reported. Stokes shift is the difference (in wavelength or frequency units) between positions of the 
band maxima of the absorption and emission spectra. 
 
 
 Cyanines represent one of the subclasses of the huge family of polymethine 
dyes.
[29,30]
 Cyanines have been used as sensitizer for emulsion photography 
and in advanced photonic materials,
[31,32]
 as well as photodynamic therapy 
agents or probes for near-infrared imaging.
[33,34] These dyes embody a π-
conjugated bridge composed of an odd number of sp
2
 carbon atoms linking 
electron-donating or -accepting groups. Photophysical properties are 
unequivocally related to the bridge length and to a minor extent to the 






Figure 11. General structure of cyanines 
 
 Rhodamine dyes are widely employed as fluorescent markers for labeling 
proteins, nucleic acids, lipids, carbohydrates, toxins, hormones and other 
biomolecules. They are used owing to their photostability, high extinction, 










Figure 12. General structure of Rhodamine derivatives 

















1.3 MRI: CONCEPTS 
 
Magnetic resonance imaging (MRI) is one of the most significant developments in 
medical imaging and it is based on the principles of nuclear magnetic resonance, 
discovered by Bloch and Purcell in 1946, for which they were awarded the 1952 
Nobel Prize.
[41,42]
 Since 1970s, MRI has evolved into an indispensable modality for 
routine clinical diagnosis and widely used tool for “in vivo” biomedical research. 
MRI was used at first for imaging the body and its role in biomedical research has 
expanded significantly in the past 20 years due to its ability to provide 
physiological and functional information. Although MRI is becoming mature, 
advances are still being made and promise to further expand its utility to many 
applications.
[43]
 MRI is attractive in clinical medicine because it provides images 
with exquisite soft tissue contrast and it is non-invasive. The use of MRI eliminates 
the need for invasive diagnostic procedures, and it has been shown to provide 
physiological information earlier in clinical investigation. The technique also offers 
fast scan times, the capacity to produce excellent quality and high-resolution 
images. It has the greatest spatial resolution and clinical potential, and can image 
structures in the millimeter range without the use of ionising radiation such as that 
used in X-ray and CT scanning. 
[44]
 In 1973, Lauterbur applied the NMR principles 
to a combination of a strong constant magnetic field and weaker and variable 
magnetic field gradients. This allowed to identify the position of a particular 
nucleus, as the strength of the field is proportional to the radiofrequency. 
[45]
 
Lauterbur did not make any hypothesis as to the potential application for this 
research, although a comment was made that there was a signal difference between 
cancerous tissue and normal tissue. Nevertheless, clear potential for the use in 
clinical imaging was realized, and as soon as few years after this idea was reported, 
prototype MRI machines were invented. In 1980, medical MRI scans started and 






The simplest form of NMR imaging involves the application of a linear magnetic 
field gradient in addition to the main static field in order to “spatially encode” 
nuclei in the subject with different resonant frequencies. The free introduction 
decay signal (FID) following a radio frequency pulse is Fourier transformed to 
yield a one-dimensional projection of signal amplitude along a particular line 
through the subject. Briefly, the net macroscopic magnetization of proton spins, 
which is aligned parallel with the applied field along the z axis, is perturbed by 
application of one or more radio frequency pulses. The component of the 
magnetization along the z axis “relaxes” back to its equilibrium value with an 
exponential time constant, T1, the longitudinal (or spin-lattice) relaxation time. The 
time dependence of the magnetization perpendicular to the z axis is characterized 
similarly by T2, the transverse (or spin-spin) relaxation time, which measures the 
time for the decay of the transverse magnetization to its equilibrium value of zero. 
In image data acquisition, the pulses are rapidly repeated for each projection. 
Tissues with short T1, values generally yield greater image intensity than those with 
longer values since the steady-state magnetization along the z axis is greater in the 
tissue with the fastest relaxation. On the other hand, short T2 values are always 
associated with lower signal intensity since this diminishes the net transverse 
magnetization available for detection. Under conditions normally employed, the 
dominant effect of a paramagnetic agent in NMR imaging is to increase the signal 
intensity of the tissue containing the agent.   
 
1.3.1 Spin-Lattice Relaxation (T1) 
 
When a RF pulse is applied, M tips towards the xy plane while processing around 
the steady external magnetic field B0. When this perturbation is terminated, the 
nuclear spin system will "relax" to the equilibrium by dissipating the excess energy 




relaxation and the equilibrium condition is reached by a first order process 
characterized by a time constant, T1, the spin-lattice relaxation time.  
 
1.3.2 Spin-Spin Relaxation (T2) 
 
When the RF pulse is applied, the moments in the xy plane begin to lose their 
precessing phase coherence, due to the natural processes that cause nuclei to 
exchange energy with each other. As a result of this process, called spin-spin 
relaxation, the net Mxy magnetization decays to zero exponentially with time, 
characterized by the time constant T2. SI1 and SI2 represent the signal intensities of 
two adjacent regions on an MR image. The magnitude of the detected signal 
depends upon the spin density (number of protons available), T1 and T2 
characteristics of tissues, chemical shift, temperature, and flow phenomena. Among 
these parameters, the relaxation characteristics are most influential to the signal 
intensity. With conventional MR imaging techniques, however, the relaxation 
characteristics of the normal and pathological conditions are often very small, 
making the accurate diagnosis based on the contrast from the MR image difficult. 
Therefore, it is important to increase the contrast between the normal tissue and 
pathological conditions on an MR image to improve the diagnostic accuracy. Since 
the variation of relaxation characteristics has a profound effect on the tissue 
contrast, the selective enhancement of tissue contrast can be achieved by the 
administration of MR contrast agents, which change the local environment of 
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1.3.3 Contrast agents  
 
MRI contrast agents (MRI CAs) are chemical compounds able to alter the 
relaxation times of water protons in tissues where they are distributed. Contrast 
agents are today used in up 50% of all MRI scans in the clinic. These molecules 
contain paramagnetic metal ion that increase the relaxation of water protons. The 
relaxation rate (ri) represents the efficiency of a contrast agent and is defined by the 
eq. 1 where (1/Ti) indicate the relaxation time of the solution of the contrast agent, 
(1/Ti)0 that of water, [CA] the c0ntrast agent millimolar concentration. 
 
                            Eq. 1 
 
In Fig. 3 essential parameters influencing the relaxivity are reported. Contrast 
agents enhance both longitudinal (1/T1) and transverse (1/T2) relaxation rates. 
Factors include the number of inner-sphere water molecules (q), the rotational 
tumbling time (τR), and the residence lifetime of inner-sphere water molecules (τM). 
A larger inner-sphere hydration (i.e.: higher q values) leads to larger relaxivity 
values. Outer-sphere relaxivity also contributes to the overall relaxivity of a 
contrast agent. Values such as a (distance of closest approach of outer-sphere water 
molecules) and τD (diffusional correlation time of outer-sphere water molecules) 







Figure 14. Variables contributing to contrast agent relaxivity 
 
1.3.4 General features for MR Contrast Agents 
 
In addition to nuclear relaxation properties, imaging contrast agents should be 
biocompatible, aside from standard pharmaceutical features such as water solubility 
and stability. The principal features requested to a good MRI contrast agent are: 
 
 RELAXIVITY: the efficiency with which the paramagnetic complex 
enhances the proton relaxation rates of water, referred to as relaxivity, must 
be sufficient to significantly increase the relaxation rates of the target tissue. 
The dose of the complex at which such alteration of tissue relaxation rates 






 “IN VIVO” DISTRIBUTION: Ideally, to be of diagnostic value, the 
complex should be localized for a period of time in a target tissue. This is a 
basic requisite in any procedure of imaging based on complexes where 
detection of the agent is usually a simple function of its tissue 
concentration.  
 TOXICITY OF METAL COMPLEXES: the "in vivo" stability and the 
tissues clearance behaviour of intravenous metal complexes affect their 
acute and chronic toxicity. It is well known that the free lanthanide ions are 
relatively toxic at doses required for NMR relaxation rate changes thus, the 
dissociation of the complex must not occur. 
[49]
 It is clear that the integrity 
of the gadolinium(III) complex must be maintained in vivo in order to 
create a safe and efficacious MRI agent.   
Toxic effects from a metal complex can derive from:  
 The free metal ion and the free ligand: In the latter two cases, 
metabolites may be more toxic than the starting compound. The 
decomplexation of the metal from the ligand generally leads to a 
higher toxicity due to the presence of the free metal in the body. 
[30] Dissociation of Gd(III) from an MRI contrast agent is highly 
undesirable. Free metal and unchelated ligands are generally more 
toxic than the complex itself. Free Gd(III) is known to bind strongly 
to serum proteins. In addition the released metal is irreversibly 
accumulates in the bones. The free ion manages to coordinate 
oxygen, nitrogen, or sulphur normally present in cell membranes 
macromolecules resulting in alterations of the dynamic equilibria 
necessary to life. Gd(III) can interfere and compete with Ca(II) 
binding sites whereas the toxicity of free ligands can be explained 
from the sequestration of common metal ions present in the body 






 The complex: The toxicity of intact metal complexes can derive 
from a wide variety of effects. The injection of large quantities of 
the ionic complexes and appropriate counter ions induces a 
difference in osmolarity between intracellular and extracellular 
compartments. Water is drawn out of cells as a result of the osmotic 
gradient, causing cellular and circulatory damages. Other possible 
mechanisms of chelate toxicity include enzyme inhibition, 





1.3.5 In vivo stability of metal complexes 
 
The complex should be efficiently excreted from the body minutes or hours after 
administration; stability is required only for its lifetime. A wide range of 
coordinating molecules, proteins and metal ions can compete for either the 
paramagnetic metal ion or its multidentate ligand. An important thermodynamic 
point for trivalent metal ions in serum is their precipitation after the interaction 
with common anions like hydroxide, phosphate, or carbonate. Both phosphate and 
carbonate are significant with respect to in this parameter.  Martell defined the 
solubilisation constant Ksol,(eq. 2) as the degree of conversion of the free ligand to 
the metal chelate where TL is the total concentration of the ligand. Low values of 
Ksol show incapacity of a ligand to solubilize the ion; alternatively, it would predict 
that the complex would be unstable with respect to metal ion precipitation. Very 
high values of Ksol would occur for a thermodynamically stable complex where no 









1.3.6  Clinically approved Gadolinium, Manganese and Iron chelates  
 
 INTRAVENOUS AGENT: Acyclic and macrocyclic polyaminocarboxylic 









 (Figure 15). 
Macrocyclic chelates are characterized by a superior thermodynamic and 
kinetic inertness with respect to the acyclic counterparts. In recent years, 
complexes of acyclic chelating agents were demonstrated to slowly 
dissociate and to be linked with pathologies such as Nephrogenic Systemic 
Fibrosis, observed in patient with kidney failure exposed to these CAs.
[52] 
 
Figure 15. Common commercially available probes 
 
Manganese(II) can be used as an alternative paramagnetic metal ion 
complexed to a ligand too. Being an endogenous metal ion, its eventual 
release from corresponding chelates raises less concerns than with 
gadolinium. A paramagnetic complex based on this metal ion was 
previously formulated and commercialised for liver imaging: Teslascan
®
 










Another class of intravenous contrast agents includes nanoparticles formed 
by iron oxides that constitute superparamagnetic centers. Their large 
magnetic influence causes distortion of the local magnetic field followed by 
an important signal loss (T2). Currently, the most used contrast agents are 
based on supermagnetic iron oxide (SPIO). After injection they are 
selectively absorbed by reticuloendothelial cells located in the liver, spleen 
and bone marrow.  
 ORAL AGENTS: oral agents are used for studying abdominal and pelvic 
structures. They are generally solutions of metal-chelate complexes 
(Magnevist
®
) or paramagnetic metal ions (ex.: ferric ammonium citrate). 
 
 
1.3.7 Classification of MRI contrast agents  
 
 






 ACYCLIC CHELATING AGENTS: DTPA was one of the first chelating 
agents employed in clinical diagnostics with Gd (Gd-DTPA), also known as 
Magnevist®. It is defined as linear or acyclic octadentate ligand which 
coordinates Gd(III) permitting the coordination of only one molecule of 
water in the inner coordination sphere. Several octadentate ligands based to 
the DTPA scaffold were synthesized, substituting acetate moiety with 
different amides (DTPA-BMA) obtaining Gd-DTPA-bisamides complexes 
with relaxivity properties similar to DTPA.  The linear structure entails low 
values of stability constant, while the high denticity is responsible of the 
relatively low values of relaxivity. Starting from the last observation, 
ligands characterized by lower denticity were recently investigated showing 
enhanced relaxivity properties.  
 CYCLIC CHELATING AGENTS: macrocyclic ligands as DOTA are 
preferable to the DTPA-like open-chain ones, as the latter show lower 
thermodynamic stability and kinetic inertness. During the last decades, the 
research in the field of cyclic chelating agents for lanthanides were widely 
explored: in this framework DO3A and its derivates as HP-DO3A were 
investigated leading to interesting results and clinically employed 
derivatives. Recently a new mesocyclic heptadentate ligand with efficient 
chelating properties was synthesized, i.e.: AAZTA. Its efficient size-match 
with small transition metal ions and lanthanides, the satisfactory 
thermodynamic and kinetic inertness award to this ligand interesting 
diagnostic application not exclusively in MRI, but also in PET, and SPECT 
techniques.  
 LIPOPHILIC CHELATING AGENTS: the introduction of a lipophilic 
alkyl chain on the skeleton of the common contrast agents supports the self-
assembly into micelles or other lipid-based nanoassemblies that exhibit 
enhanced values of r1. In addition to this, lipophilic CAs can further form 




increments in the relaxivity due to the reduced and lower mobility of the 
systems: example of lipophilic MRI-CAs are Gd-DTPA-DMPE and Gd-
AAZTA-C17 with potential applications for in vivo imaging of tumours and 
cardiovascular diseases.  
 BIFUNCTIONAL CHELATING AGENTS (BFCAs): they were introduced 
with the aim to add more selectivity to the contrast agents linking itself to a 
targeting vector. The most common BFCAs derive from cyclic and acyclic 
polyaminopolycarboxylic acids similar to DTPA, DOTA and AAZTA, on 
which a suitable versatile and reactive functional group is added, without 

























1.4 NUCLEAR MEDICINE IMAGING: SPECT AND PET 
 
Nuclear medicine imaging is based on the principle of tracers and primarily gives 
images of function, including physiology, biochemistry or metabolism, by 
analyzing the dynamic behaviour of molecules in organs and tissues. Nowadays 
SPECT and PET are the dominant imaging techniques in nuclear medicine. 
Changes in function often anticipate changes in anatomy in various disease 
conditions. Accordingly, nuclear medicine imaging may be useful for early 
diagnosis of disease and for assessment of treatment effects in the early post-
therapeutic stage. Single-photon emission computed tomography (SPECT) and 




PET requires the injected drug to be labelled with a positron-emitting radionuclide. 
When radionuclide decays, it expels a positron from its nucleus, which travels a 
short distance before being destroyed with an electron to release two γ rays 
(moving in the opposite direction), detected by the PET scanner. 
SPECT requires the use of a contrast agent labelled with a γ-emitting radionuclide. 
These γ rays are recorded by the detectors of a dedicated gamma camera and after 
that the signal is processed, it can be converted into an image identifying the tracer 
localization. In both situations after an enough acquisition time, the data are 
elaborated by computer using complicated algorithms to produce images of the 
radiotracer’s location within the organism. PET and SPECT use 
radiopharmaceutical compounds to provides images. Radiopharmaceuticals are 
drugs containing a radionuclide, and are used routinely in nuclear medicine for the 
diagnosis or therapy of various diseases. 
[54]
 Intravenous injection is the favourite 
modality to administer radiopharmaceuticals. They are mostly small organic or 




Radiopharmaceuticals are above all small organic or inorganic compounds but they 
can also be biomolecules such as monoclonal antibodies and antibody fragments 
labelled with a radionuclide.  
Diagnostics and therapeutics are the two main classes of radiopharmaceuticals. 
Another kind of classification may be associated to the type of biodistribution: 
those whose distribution into the body is determined only by their chemical and 
physical properties; and those whose distribution is determined by their receptor 











Indium-111 pentetate  
 
Indium-111 oxyquinoline   
Samarium-153 EDTMP  
  
Tc-99m Bicisate (ECD)   
 
Tc-99m Disofenin (DISIDA) 
   
Tc-99m Exametazine (HMPAO)  
 
Tc-99m Gluceptate   
 
Tc-99m Lidofenin (HIDA)   
 
Tc-99m Mertiatide   
 
Tc-99m Oxidronate (HDP)   
 
Tc-99m Pentetate (DTPA)   
 
Tc-99m Sestamibi    
                                                                         
Tc-99m Succimer (DMSA)  
   
Tc-99m Teboroxime  
   
Tc-99m Tetrofosmin 
 
Indium-111 DTPA®  
 
Indium-111 oxine®  
Quadramet®   
Neurolite®  
    
Hepatolite®  
     
Ceretec®   
      
Glucoscan®  
    
Technescan® HIDA  
    
Technescan® MAG3 
    
Osteoscan® HDP                           
  
Techneplex®, Technescan®         
     
Cardiolite®, Miraluma®  
          
DMSA®    
   
Cardiotec®  
   
Myoview®  
 
Imaging of CSF kinetics 
 
Labeling leukocytes and platelets 
Palliative treatment of bone pain 
 
Cerebral perfusion imaging 
 
 Hepatobiliary imaging 
 










 Renal imaging and function studies 
 
Myocardial perfusion imaging 
Breast tumor imaging 
Renal imaging 
 
Myocardial perfusion imaging 
 
Myocardial perfusion imaging 
 
 
    
Table 2.  List of selected examples of commercial “small molecule” radiopharmaceuticals, along 














Figure 18. Structures of selected radiopharmaceuticals based on small metal complexes. 
 
Diagnostic radiopharmaceuticals are molecules labelled with positron-emitting 
isotopes for positron emission tomography (for PET) or gamma-emitting isotopes 
for single photon emission computed tomography (for SPECT). As a rule, 
diagnostic radiotracers do not have pharmacological effect and they are dosed in 
















 has been used for diagnosis of thyroid 
disease due to the similarity with iodide. Subsequently a lot of 
99m
Tc complexes 





1.4.1  Target-specific radiopharmaceuticals 
 
Currently, one of the biggest issues in the molecular imaging research is the probe 
specificity. Development of targeted-specific radiopharmaceuticals will be the 
future in this field. In this strategy, radiotracers are conveyed to the diseased tissue 
where will interact with a specific receptor. Image quality may be increased by 
channelling a large amount of radiotracer in the desired tissue, then the toxicity 
may be reduced. The high specificity of receptor binding results in selective uptake 




of biomolecules, including monoclonal antibodies, antibody fragments and small 
peptides, have been studied as ‘‘carriers’’ for radionuclides and a part of these have 










Indium-111 capromab pendetide 
Indium-111 pentetreotide  
Indium-111 satumomab pendetide  
 
Tc-99m Apcitide    
Tc-99m Arcitumomab   
Tc-99m Depreotide  
 
 
Y-90 Ibitumomab tiuxetan  
 










Zevalin   
Bexxar ® HIDA 
  
 
ProstaScint1 Imaging of prostate cancer 
Imaging of neuroendocrine tumors 
Imaging of metastatic disease associated with 
colorectal and ovarian cancer 
Synthetic peptide for imaging DVT (deep vein 
thrombosis) 
Monoclonal antibody for colorectal cancer 
Somatostatin receptor-bearing pulmonary 
masses 
Treatment of non-Hodgkin’s lymphoma 
 
Treatment of non-Hodgkin’s lymphoma 
 














1.4.2 Coordination chemistry and design of radiopharmaceuticals 
 
The general strategies for the design of a radiopharmaceutical are: 
 
 Integrated approach: the substitution of a part of a known strong affinity 
receptor ligand with an "unnatural" metal chelate is the basic principle of 
integrated approach. In this way the conformation, size changes and 
receptor binding affinity remain unchanged. Unluckily this method often is 
complicated and the final receptor binding affinity is too low.
[57]
 
 Bifunctional approach: The bifunctional approach uses a high affinity 
receptor ligand as the targeting biomolecule such as monoclonal antibodies, 
small peptides, peptidomimetics, or nonpeptide receptor ligands. The 
typology and oxidation state of the radiometal are essential criteria to select 




 Hybrid approach: the radiometal is chelated by a tripeptide sequence (such 
as Gly-Gly-Gly, Cys-Gly-Gly, or Cys-Gly-Cys) containing an N4, N3S, or 
N2S2 donor set.
[54]
 the tripeptide sequence can be included in a bigger 
peptide structure that can be linear or cyclic. Though this method has been 




Re-labeled a-melanocyte-stimulating hormone 
peptide analogues the efficacy of this approach for the production of a big 












1.4.3  Radiometals  
 








C are used for PET 
investigation. They are produced by means of a cyclotron.  
18
F-FDG is the radiolabeled analogue of glucose and today it is the most important 
tracer used for PET analysis. Because the supply of glucose is increased in many 
malignancies, the use of 
18
F-FDG is essential for detecting and monitoring the 
tumour presence or the therapy efficacy. It is an important tool for the evaluation of 
glucose metabolism in the heart and brain and it has been recently approved for 
Alzheimer's diagnosis. 
Figure 20. Structure of Fludeoxyglucose (
18
F). Studies with 18F-FDG in a normal subject and a 
subject with dementia due to Alzheimer’s disease. 
 
Amyvid™ is another example of a molecular imaging agent containing 
18
F and it is 
able to bind β-amyloid aggregates, and it is intended for use with PET imaging of 
the brain. It is a sterile, non-pyrogenic radioactive diagnostic agent for intravenous 
injection. It is useful to investigate the brain pathology and to estimate β-amyloid 
plaque density in adult patients with cognitive impairment who are being evaluated 












Figure 21. Amyvid™ (E)-4-(2-(6-(2-(2-(2[18F]-fluoroethoxy)ethoxy)ethoxy)pyridine-3-yl)vinyl)-N-
methylbenzamine. 
 
Above mentioned isotopes are incorporated into small molecules but owing to their 
short half-lives and rapid clearance they are not suitable for long term analyses. 
[53]
 
The time required to purify the radioisotopes, to incorporate it into a carrier agent, 
the packaging and transport of the resultant radiopharmaceutical across distant 
locations must be considered and the radiotracer half-life is a central issue. 
Radionuclides derived from Zr, Y, In, Ga, and Cu isotopes have a longer half-life 
and they have been investigated as radionuclide labels for biomolecules because 
they have the potential to combine a nearly optimal decay profile with the 




Recently PET radioconjugates specific for tumour-associated receptors have been 
introduced in clinical routine use. They may extend PET applications for in vivo 
quantification of receptor expression and its possible changes during the course of 
cancer therapy. 
[61]
 In this regard the most prominent examples are 
68
Ga-labeled 
somatostatin analogues for detect and follow neuroendocrine tumours. 
[62,63,64]
  
At the same time other radiometals have witnessed a growing interest for nuclear 
techniques as zirconium and scandium. In particular the 3.97 hours half-life of 
44
Sc 
and its high positron branching of 94.27% and promote the application of 
44
Sc as  
radiopharmaceutical for PET. 
[64]
 The ligands already used in gadolinium(III)-based 
magnetic resonance imaging (MRI) contrast agents may be used for the chelation 
of these radiometals and derivatives of DTPA and DOTA are the first choice. More 







1.4.4 Production of radionuclides  
 
The radionuclides most commonly used are generated by a cyclotron or, less 
commonly, using a linear accelerator. The spectrum of radionuclides that may be 
produced is dependent of the accelerator energy. Nowadays accelerators with 
different energies are sold by several industries. 
18
F is a dominant example of 
radionuclide used in clinics and produced by accelerator. It is produced by proton 
bombardment of a stable oxygen-18 (
18









C 20.385 min. 
13
N 9.965 min. 
15
O 2.037 min. 
18
F 109.77 min. 
61
Cu 3.33 hours 
64
Cu 12.7 hours 
86
Y 14.74 hours 
124
I 4.176 days 
110










Table 4. Data on the half-life of radionuclides are reported 
 
The “generator” is another tool able to provide radionuclides decaying into 
"daughter" radionuclides with much shorter half-lives. The "parent" radionuclide is 
chemically bound to an ion exchange column and the ‘daughter’ radionuclide 








Ge generator is remarkable for oncology: its long production useful life 
combined with the short half-life of 
68























Rb 1.273 min. 
 










radionuclide generators is shown Figure. 
[67] 
a) Cation exchange-based (Mainz): (1) generator elution through cation-exchange cartridge, (2) 
desorption of purified 
68




b) Anion exchange-based (Hannover/Heidelberg): (3) generator elution into HCl reservoir, (4) 
second elution through anion-exchange catridge, (5) desorption of purified 
68
Gd using water 
c) Fractionation (Rotterdam): (6) identification of the eluate fraction and use without further 
purification   
 
Kinetic and thermodynamic stability, redox properties, stereochemistry, 
coordination chemistry, the charge and lipophilicity are important criteria for the 
choice of the radiometal. In both production methods the security of final 
radiometals is essential.  Chemico-physical analyses are routinely performed, such 
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2.0 OUTLINE OF THE THESIS  
The entire PhD period was devoted to the design, preparation and preliminary 
evaluation of novel potential probes for diagnostic imaging applications. Rather 
than selecting a single diagnostic technique among the large number of actually 
available ones, we decided to focus our research activity on the development of 
small-sized target compounds, holding specific molecular properties of potential 
interest for one or (better) more diagnostic techniques. In this contexts were 
developed the first two topics of this PhD thesis, both involving the study of 
chelating agents. Chelating agents are widely employed for the coordination of 
metal ions and when the metal ion plays a role in the diagnostic technique the 
chelator is essential to allow its safe introduction in the living organism, to mask its 
toxicity and optionally to enhance specific physico-chemical property and to target 
the complex towards selected organs and/or tissues. Acyclic chelating agents such 
as derivatives of the archetypal EDTA and the homolog DTPA are generally a first 
choice for the chelation of metal ions of diagnostic and therapeutic interest. 
Unsurpassed thermodynamic inertness of metal complexes of macrocyclic ligands 
led to the election of this family of chelating agents as the “gold standard” for in 
vivo applications. Nevertheless, their slow kinetic of complex formation is still an 
open issue in nuclear medicine, where short-lived isotopes are routinely used. 
The search for alternative chelating agents is very active because the properties of 
the currently employed compounds are far to be optimal. Much work has to be 
done in terms of stability, selectivity and other important features such as the easy 
conjugation to other molecules, (bio)degradability and not last an easy synthetic 





The first topic of the present thesis involved the design and preparation of a novel 
chelating agent. The latter was built in a very simple process, taking advantage of a 
widely available commodity chemical. The structure of the hexadentate ligand 
includes two amines and four carboxyl groups, placed in a stereochemically 
controlled fashion on a substituted cyclohexane ring. The unusual arrangement of 
donor groups of this novel compounds was the subject of the potentiometric 
determination of its protonation and stability constants. The affinity data registered 
for different metal ions allowed us to delineate the behaviour of this original 
chelating agent. 
The experience in the potentiometric determination of solution thermodynamic data 
gained during the period spent in the Department of Inorganic and Analytical 
Chemistry of the University of Debrecen was directly applied in the second section 
of the PhD activity. In this task, we explored the possibility to expand the use of a 
chelating agents previously developed in our research group (AAZTA) for a metal 
ion recently resurged to the interest of the nuclear medicine community, i.e.: Sc
3+
. 
The positron emitting isotope 
44
Sc is characterized by its relatively long half-life, 
allowing a wider time window for diagnostic imaging purposes; moreover, it can 
be obtained by a dedicated generator, allowing a more practical and cyclotron-
independent in situ use. The coordination chemistry of Sc
3+
 is scarcely explored 
and we were prompted to evaluate the affinity of the chelating agent AAZTA 
towards this trivalent metal ion, using a combination of potentiometric and 
spectrophotometric techniques. 
An additional topic of the present thesis involved the search for novel molecular 
scaffolds for optical imaging applications. The latter usually relies on established 
chromophores or luminophores, with the molecular diversity represented by large 
variations in the pattern of substituents.  
We decided to explore different molecular bases for the development of optical 
imaging probes and turned our attention to two specific families of compounds: 




Perimidines are trinuclear diazaheterocycles synthesised from 1,8-
naphthalenediamines and easily functionalised on the pyrimidine moiety, allowing 
large structural modulations. During the PhD period a series of 2-substituted 
perimidines was synthesized in order to evaluate its photophysical properties. All 
the synthesized compounds showed significant fluorescence, and a detailed study 
of absorption, emission and quantum yield allowed to trace the general properties 
of perimidines and to learn on the influence of the substituents. 
Aminoquinones, aminoquinomethides and derivatives were considered as potential 
scaffolds for optical imaging applications mainly due to their “push-pull” electronic 
features, leading to unusually high absorption wavelengths. An easy synthetic 
access, combined with an almost unlimited variation of the substituents and 
optional benzo- o hetareno- ring fusion, represent an interesting starting point for 
the design of chromophores reaching the near-infrared optical window of biological 
tissues. Exploring the chemistry of aminoquinomethides we met an unprecedented 
reaction sequence leading to the efficient preparation of highly coloured 
diaminoquinones, starting from simple compounds as vanillin. The reaction 
sequence was studied in detail, allowing to outline the likely mechanism and the 
structural versatility. Preliminary toxicological tests on diaminoquinones showed 
an almost complete absence of effects on different cellular lines and suggesting the 















cis-IPDTA: an Original Polyaminopolycarboxylic Chelating Agent from 
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An original diaminotetracarboxylic acid chelating agent (cis-IPDTA, cis-
isophoronediamine-N,N,N’,N’-tetraacetic acid) was prepared starting from 
commercially available isophoronediamine. Its protonation constants and the 
stability of selected metal complexes were determined by potentiometric titrations. 
The coordination behavior of cis-IPDTA was compared with that of the linear 




Polyaminopolycarboxylic acids represent the most important class of synthetic 








 Despite such 
impressive commercial interest, this huge market is dominated by just three 
compounds, NTA, EDTA and DTPA, depicted in Figure 1, with less than a dozen 



















Figure 1: The polyaminopolycarboxylic acid ligands NTA, EDTA and DTPA.  
 
The research in this area is still active as several issues in the design of complexing 
agents are far to be considered satisfactory, such as the specificity and selectivity 




 The large scale involved 
in the different applications of chelating agents lead to the inclusion of the 
production cost as a critical factor in an overall evaluation of new potential 
candidates. 
In the search of original ligands with improved properties we recently designed and 
synthesized novel compounds with unusual molecular skeletons as AAZTA,
[6]
 a 
mesocyclic triaminotetracarboxylic acid showing remarkable affinity for several 
metal ions of diagnostic and therapeutic interests,
[7,8]
 and NORDATA, a bicyclic 
diaminotetracarboxylic derivative featuring a rigid molecular structure.
[9] 
Furthermore, heterocyclic s-triazine derivatives embodying two hydrazino-N,N-








Isophoronediamine (IPD) is a commodity chemical produced in large amounts as 
an intermediate for the preparation of isophorone diisocyanate, an important 
building block widely employed for the preparation of polyurethanes and in the 
modification of alkyd resins. IPD is used as such as hardener for epoxy resin and 
as intermediate in the preparation of the corresponding diisocyanate.
[12]
 Despite its 
wide availability and low price, this diamine found scarce use in organic synthesis, 
a recent example being the preparation of a diurea-based catalyst used to perform a 
stereoselective variant of the Morita-Baylis-Hillmann reaction.
[13] 
Here we describe the synthesis and the complexation behavior of a new 
polyaminopolycarboxylic acid-based ligand, cis-IPDTA (cis-
isophoronediaminetetraacetic acid), built by placing four coordinating 




2.1 - Material and methods 
 
The chemicals used for the experiments were of the highest analytical grade. 
Isophoronediamine  was obtained from Sigma-Aldrich; the resolution of the 
diastereomeric mixture to obtain diastereomerically pure racemic (±)-cis-
isophoronediamine is reported in literature.
[14]
 The metal chlorides solutions were 
prepared from the corresponding commercially available salts (Aldrich, 99.9%). 
The concentration of CaCl2, MnCl2, Pb(NO3)2, Cd(NO3)2, ZnCl2, CuCl2 and LnCl3 
solutions were determined by complexometric titration with standardized 
Na2H2EDTA and Xylenol Orange (ZnCl2, Pb(NO3)2, CdCl2, LnCl3), murexide 
(CuCl2), Patton & Reeder (CaCl2) and Eriochrome Black T (MnCl2) as indicators. 




in the presence and absence of a large (40-fold) excess of CaCl2. The pH-
potentiometric titrations were made with standardized 0.2000 M KOH. Liquid-
phase NMR experiment were recorded on a JEOL ECP300 (7.04 T) spectrometer. 
 
2.2 – Synthesis 
 
2.2.1 - Tetra-tert-butyl isophoronediamine-N,N,N’,N’-tetraacetate (cis-IPDTA-
(tBu)4) 
 (±)-cis-Isophoronediamine (1.0 g, 5.9 mmol) was dissolved in acetonitrile (30 
mL). tert-Butyl bromoacetate (3.85 mL, 26.1 mmol, 4.4 eq) and potassium 
carbonate (8.18 g, 59.3 mmol, 10 eq) were sequentially added and the resulting 
reaction mixture was stirred at room temperature 24 hours, checking periodically 
by TLC. The solvent was removed by evaporation under reduced pressure. The 
resulting oil was redissolved with dichloromethane and washed thrice with a 
saturated NaHCO3 solution of sodium bicarbonate and twice with brine. The 
organic phase was dried over anhydrous Na2SO4, filtered, and the solvent was 
removed by evaporation under reduced pressure. The resulting crude oily product 
was purified by gravimetric chromatography on silica-gel column (petroleum 
ether/ethyl acetate 95:5 to 9:1), yielding cis-IPDTA-(tBu)4  (1.45 g, 2.3 mmol, 
39%) as a light yellow oil. 
1
H-NMR (CDCl3, 300 MHz, 298K) δ: 3.42 (s, 4H), 3.39 
(s, 4H), 3.06-2.93 (m, 1H), 2.38 (s, 2H), 1.62-1.40 (m, 2H), 1.43 (s, 18H), 1.42 (s, 
18H), 1.15-0.78 (m, 4H), 0.96 (s, 3H), 0.94 (s, 3H), 0.88 (s, 3H). 
13
C-NMR (CDCl3, 
75.4 MHz, 298K) δ: 171.3 (2C), 80.6 (2C) 71.8 (CH2), 58.7 (CH2), 55.0 (CH), 53.5 
(CH2), 47.4 (CH2), 43.5 (CH2), 39.1 (CH2), 38.7 (C), 35.6 (CH3), 32.0 (C), 28.25 
(CH3), 28.16 (CH3), 27.9 (CH3), 23.6 (CH3). ESI-MS (+): m/z calcd for 











2.2.2 - Isophoronediamine-N,N,N’,N’-tetraacetic acid (cis-IPDTA) 
 
cis-IPDTA-(tBu)4 (1.04 g, 1.66 mmol) was dissolved at room temperature in 
trifluoroacetic acid (10 mL) and the resulting reaction mixture was stirred at room 
temperature for 3 days. The solvent was removed under reduced pressure and the 
resulting oil was dissolved in methanol and precipitated with diethyl ether. This 
purification procedure was repeated 3 times, affording cis-IPDTA (900 mg, 1.43 
mmol) as a white powder. 
1
H-NMR (D2O, 300 MHz, 298K) δ: 4.03 (s, 8H), 3.76 
(bt, 1H), 3.19 (s, 2H), 1.88-1.77 (m, 2H), 1.50-1.18 (m, 6H), 1.22 (s, 3H), 0.98 (s, 
3H), 0.94 (s, 3H). 
13
C-NMR (D2O, 75.4 MHz, 298K) δ: 169.21 (C), 169.17 (C), 
70.2 (CH2), 61.4 (CH), 59.4 (CH2), 53.5 (CH2), 45.9 (CH2), 37.9 (C), 36.2 (CH2), 
35.3 (C), 34.1 (CH3), 31.7 (CH2), 26.6 (CH3), 22.1 (CH3). ESI-MS(-): m/z calcd for 






2.3 Potentiometric titrations 
 
The protonation and the stability constants of some metal complexes formed with 
cis-IPDTA ligand were determined by pH-potentiometric titration. The metal-to-
ligand concentration ratios were 1:1 and 2:1 (the concentration of the ligand was 
generally 0.002 M). For the pH measurements and titrations, a Metrohm 785 DMP 
Titrino titration workstation and a Metrohm-6.0233.100 combined electrode were 
used. Equilibrium measurements were carried out at a constant ionic strength (0.1 
M KCl or KNO3) in 6 mL samples at 25 C. The solutions were stirred, and N2 was 
bubbled through them. The titrations were made in the pH range of 1.7-11.7. KH-
phthalate (pH=4.005) and borax (pH=9.177) buffers were used to calibrate the pH 
meter. For the calculation of [H
+
] from the measured pH values, the method 
proposed by Irving et al. was used.
[15]
 A 0.01M HCl or HNO3 solution was titrated 
with the standardized KOH solution in the presence of 0.1 M KCl or KNO3 ionic 






]) values were used to obtain the equilibrium H
+
 concentration from the pH 
values, measured in the titration experiments. The protonation and stability 
constants were calculated with the PSEQUAD software.
[16]  
 
Results and discussion 
 
The structural features of IPD (5-amino-1,3,3-trimethylcyclohexanemethylamine) 
are represented by two primary amine groups on the central saturated six-
membered ring, placed in different chemical environments. A first amine group is 
directly linked to the cyclohexane residue while the second one is linked to the ring 
through a single -CH2- group. Three methyl groups complete the molecule 
introducing some steric hindrance. The molecule is chiral with C-1 and C-3 being 
the stereocentres and giving rise to an overall count of 4 stereoisomers.  In 
principle IPD may appear to be a non-optimal candidate for the preparation of 
chelating agents, as the two donor nitrogen atoms are separated by 4 carbon atoms. 
Metal chelation would lead to the formation of 7-membered rings, reported to show 
lower stability compared with 5- or 6-membered chelate rings. Nevertheless, the 
presence of the cyclohexane ring introduces an element of strong structural rigidity 
that could counterbalance the unfavourable entropic factor represented by the long 
inter-nitrogen distance. Furthermore, Berkessel et al. reported a method to isolate 
selectively the cis-isomer of IPD, based on the selective absorption of carbon 
dioxide to form the alcohol-insoluble carbamic acid, subsequently decarboxylated 
by thermal treatment.
[14] The cis-stereochemistry places the coordinating nitrogen 
atoms on the same side of the ring plane, possibly inducing the formation of 
chelates. 
The amine groups in cis-IPD may be located in an equatorial-equatorial (eq-eq) or 
in an axial-axial (ax-ax) disposition as a consequence of ring-flipping phenomena 
(Scheme 1). The eq-eq disposition is not suitable for metal chelation due to the 




two amines to reside in equatorial positions of the free chelating agent, while they 
are forced in the less-stable diaxial positions when implicated in the coordination 









Scheme 1. Conformational equilibrium for cis-IPD. 
 
In this work we report the functionalization of the nitrogen atoms with four 
carboxymethyl residues, completing the assembly of the potentially hexadentate 
original chelating agent (cis-)IPDTA. Functionalization is achieved by exhaustive 
alkylation with t-butyl bromoacetate in acetonitrile in the presence of potassium 
carbonate (Scheme 2). Standard removal of the t-butyl groups with neat TFA yields 
the desired ligand, whose behavior with a wide array of metal ions is studied by 
means of potentiometric techniques. The thermodynamic behavior of the cyclic cis-
IPDTA was compared with that of the linear congener BDTA (1,4-butanediamine-
N,N,N’,N’-tetraacetic), sharing the same distance between the two iminodiacetic 
functions (i.e.: 4 carbon atoms). This comparison is intended to evaluate the 
contrasting effects on the metal chelation of the conformational issues. In principle, 
IPDTA (or its derivatives) can behave as heteroditopic coordinating agent, since the 
iminodiacetic moieties are located in a different chemical environment. Nevertheless, 
the resulting dinuclear complexes would be characterized by a considerable loss of 






























Scheme 2. Synthesis of cis-IPDTA. a) BrCH2COOtBu, K2CO3, CH3CN, r.t., 24h; 
b) TFA, r.t., 3d. 
 
3.1 – Synthesis 
 
The synthetic pathway employed for the preparation of cis-IPDTA is depicted in 
Scheme 2. The commercial mixture of IPD isomers was separated using the 
literature procedure reported by Berkessel et al.,
[14]
 affording the racemic cis-IPD 
with good diastereomeric excess (de > 98%). cis-IPD was peralkylated with tert-
butyl bromoacetate in the presence of potassium carbonate in acetonitrile, leading 
to cis-IPDTA-(tBu)4. Treatment with trifluoroacetic acid and precipitation with 







3.2 Equilibrium studies 
 
3.2.1 Protonation equilibria: The complexation properties and protonation 
equilibria of the cis-IPDTA ligand have not been studied previously. (The charges 
of ionic species will be used only when it is necessary). The protonation constants, 








                                                        (1)                                                                                                                                    
where i=1, 2…5. The obtained 
H
i
logK  values are listed and compared with those of 
H4BDTA and H2Cy-IDA (N-cyclohexyliminodiacetic acid) in Table 1. Standard 
deviations (3) are shown in parentheses.  
 





I 0.1 M 
KCl 
0.1 M KNO3 0.1 M KNO3 0.1 M KNO3 
logK1
H
 11.23 (1) 11.21 (2) 10.66 10.81 
logK2
H
 8.34 (1) 8.34 (2) 9.05 2.15 
logK3
H
 2.53 (1) 2.59 (2) 2.45  
logK4
H
 1.73 (2) 1.67 (3) 1.90  
logK5
H
 1.25 (3) 1.23 (4)   
logK4











Comparison of the protonation constants of cis-IPDTA with those of BDTA 
indicates that the logK1
H
 value of cis-IPDTA is higher, whereas its logK2
H
 value is 
somewhat lower than those of the BDTA. Since the logK1
H
 value of cis-IPDTA is 
similar to that of Cy-IDA, it can be assumed that the first protonation takes place 
on the nitrogen atom (a) of the iminodiacetate moiety directly linked to 




distal nitrogen atom (b) of the ligand. The third, fourth and fifth protonation steps 
of cis-IPDTA are related to the protonation of the carboxylate groups. The logK4
H
 
value of cis-IPDTA ligand is comparable with the same parameter of BDTA (Table 
1). According to the logK4
H
 values presented in Table 1, it can be assumed that 
the complexes of cis-IPDTA and BDTA ligand are characterized by similar 
stabilities. However, in determining the stability constants of the cis-IPDTA 
complexes, the presence of the less flexible cyclohexyl group may also play an 
important role. So, the equilibrium study of the metal complexes formed with the 
cis-IPDTA may give some new information about the effect of the less flexible 
ligand backbone on the metal-donor atom interaction and the thermodynamic 
stability of the metal complexes.  
 
3.2.2 Complexation properties of cis-IPDTA: The stability and protonation 
constants of the metal complexes formed with the cis-IPDTA ligand are defined by 
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 ions have been 
calculated from the pH-potentiometric titration data obtained at 1:1 and 2:1 metal 
to ligand concentration ratios. In calculating the equilibrium constants, the best 
fitting of the mL KOH – pH data has been obtained by assuming the formation of 
ML, MHL, MH2L and M2L complexes The formation of the deprotonated [M(cis-
IPDTA)H-1]
2-
 complexes takes place at pH>9.5, indicated by the base consumption 








-ions in ZnL, CuL, PbL and CdL complexes. The pH-potentiometric 





 ions at 1:1 metal to ligand concentration ratio are shown in Figures 2 and 3, 
























 ions ([cis-IPDTA]= [M
2+
]=2.00 

















 ions ([cis-IPDTA]= [Ln
3+
]=2.00 mM, [HCl]=4.00 
























The stability and protonation constants of complexes of cis-IPDTA, BDTA and 
Cy-IDA (IDA) ligands with several metal ions, (investigated by pH-potentiometry) 
are reported in Table 2. 
 
Table 2. The stability (logKML) and protonation (logKMHiL) constants of metal 








I 0.1 M KCl 0.1 M KNO3 0.1 M KNO3 0.1 M KNO3 
CaL 4.28 (3) 5.54 3.34 2.59 
CaHL 9.46 (3) 8.65   
Ca2L 1.39 (8) 1.42   




MnHL 8.25 (3) 6.57   
Mn2L 2.71 (5) 1.78   
CuL 14.32 (2) 17.25 11.04 10.63 
CuHL 6.53 (2) 4.19  2.3 
CuH2L 2.36 (2)    
CuLH-1 11.28 (3)  8.07 8.5 
Cu2L 7.34 (2)    
ZnL 11.59 (2) 14.89 7.60 7.27 
ZnHL 6.05 (1) 3.10   
ZnH2L 3.66 (1)    
ZnLH-1 11.78 (4)    
Zn2L 2.55 (3)    
*PbL 9.15 (4) 10.38  7.35 
PbHL 8.37 (3) 7.63  3.84 
PbLH-1 9.68 (5)   9.36 
Pb2L 5.26 (8) 5.45   
*CdL 9.89 (3) 11.89 6.94 5.73 
CdHL 7.14 (3) 5.50   





Cd2L 2.60 (5) 2.22   
LaL 6.64 (5) 9.04  5.88
[d]
 
LaHL 8.43 (5) 7.70   
GdL 8.54 (4) 9.90  6.68
[d]
 
GdHL 6.81 (7) 6.70   
LuL 9.43 (5) 11.40  7.61
[d]
 
LuHL 6.09 (8) 6.60   
































Figure 4. logKML values of the cis-IPDTA as a function of the ionic radius of the 
metal ions. 
 
The stability constants of the metal complexes formed with cis-IPDTA (Table 2 
and Figure 4) are generally about 2 – 3 orders of magnitude lower and higher 
than those of the corresponding BDTA and Cy-IDA or IDA complexes, 










 complexes formed with BDTA and cis-IPDTA complexes are 
about 3 - 3.5. By taking into account the size of the investigated metal ions, it 










































 complexes formed with cis-IPDTA are higher than it can be expected 
according to the trend of the logKML values presented in Figure 4. 





 (Figure 4 and Table 2). This behaviour is similar to that found 
for the Ln(BDTA) and Ln(IDA) complexes. On the other hand, the stability 
constants of the Ln(cis-IPDTA) are significantly lower than those of 
Ln(BDTA) but the differences between the logKLnL values significantly increase 
from the Gd
3+
 and it is 2 logK unit for the Lu
3+
. These data clearly indicate the 
effect of the rigid ligand backbone on the trend of the logKLnL values across the 
lanthanide series. 
The complexes formed with the cis-IPDTA, similarly to those of BDTA, can be 
protonated and the protonation constants have been determined by pH-
potentiometry (Table 2). Two protonation constants could be determined for the 




 ions. According to the first protonation 
constants (logKMHL = 6.0 - 9.5) it can be assumed that the metal ion is 
coordinated by the iminodiacetate moiety (a) attached to cyclohexyl-ring, 
whereas the protonation occurs at the nitrogen atom (b) of the non- or weakly-
coordinated iminodiacetate fragment. The free or weakly coordinated 
iminodiacetate moiety in the ML complexes can lead to the formation of the 





complexes there is evidence of one non-coordinated donor atom (carboxylate-













cis-IPDTA, a new polyaminopolycarboxylic ligand from isophoronediamine, was 
prepared from the commercially available commodity isophoronediamine. The 
protonation constants of this hexadentate ligand were determined by pH-
potentiometric analysis. The formation and protonation constants of the complexes 
with various metal ions were investigated, in order to characterize the complexation 
behavior of cis-IPDTA. The thermodynamic behavior of this ligand was compared 
with that of the linear congener BDTA. The results suggest a strong effect of the 
conformation of cyclohexane ring on the chelation of metal ions by mean of the 
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Noninvasive imaging modalities have recently allowed increased opportunities for 
molecular diagnostic and therapeutic procedures. Molecular imaging (MI) is the 
visualization, characterization, and measurement of biological processes at the 
molecular and cellular levels in humans and other living systems.
[1]
 Specific MI 
agents are usually needed to generate a contrast useful for the diagnostic content of 
the images. The most sensitive molecular imaging techniques are positron emission 
tomography (PET) and single photon emission computed tomography (SPECT).
[2]
 




C were incorporated into small molecules, 
but their often lengthy syntheses combined with short half-lives and rapid clearance 
lead to a limited time-window available for imaging, restricting the investigation of 
biological processes.
[3]
 The enduring development of biological targeting agents 
such as proteins, peptides, antibodies and nanoparticles, stimulated the need to 
introduce radionuclides with half-lives matching their biological properties.
[4]
 In 




radionuclide labels for biomolecules due to their longer and favorable decay 
characteristics.
[3]
 In addition, the development of radionuclide portable generators 
and small biomedical cyclotrons able to produce radiometals allows to overcome 
the dependence on nuclear reactors and accelerators for the availability of 
radionuclides. Furthermore, the use of metal ions requires a single complexation 
step to prepare the diagnostic probe. This is exemplified by the recent development 




, t½ = 67.71 min), a radionuclide used for PET 





In the last years 
44
Sc raised a significant interest because it combines a relatively 
long half-life (3.97 hours, Emean (β
+
) = 632 keV) with its high positron branching of 
94.27%, being of potential interest for PET applications.
[5]
 The use of this nuclide 





Sc can be more easily employed to synthesise a wider variety of 
radiotracers with longer pharmacokinetic profiles, leaving more time to transport it 
to more distant PET facilities. 
44
Sc is currently produced via cyclotronirradiation of 
44













To date, a limited number of studies have been devoted to the coordination 
chemistry of this interesting metal ion, except for some report on organometallic 
derivatives. Its application as a PET radiopharmaceutical requires a chelating agent 
exhibiting a fast complex formation kinetic, in order to prepare the final probe with 
the minimum erosion in its useful emitting lifetime. Furthermore, to avoid the 
dissociation of the metal ion with concomitant toxic effects, the resulting chelate 
should show excellent thermodynamic stability and kinetic inertness. Scandium(III) 
complexes with DOTA and DTPA
[5,12,13]
 displayed high formation constants; 





 chelate was conjugated with a dimeric cyclic RGD 
peptide for the visualization of integrin ανβ3, an important factor linked to tumour 






The heptadentate ligand AAZTA is a recent entry in the realm of chelating agents. 
It is easily prepared in 3-4 synthetic steps, and its coordination properties towards a 
wide array of metal ions have been studied in detail, showing a remarkable affinity 
for lanthanides and transition-metal ions. Thermodynamic, kinetic and structural 






, three metal ions of PET 
interest, demonstrating good stability values for the resulting chelates. Lipophilic 
and tailored derivatives of this ligand have been studied, allowing to include 
AAZTA in lipid-based nanoparticles or to interact with proteins and molecular 
hosts.
[15-18]
 Recent efforts were devoted to the development of bifunctional 
chelating agents (BFCAs)
[19,20]
 based on the AAZTA platform,
[21-24] 
paving the way 
for the conjugation of this versatile ligand to vectors for targeting purposes.
 
Prompted by the renewed interest toward 
44
Sc as PET-imaging radiometal, we 
started a systematic study of the thermodynamic and kinetic properties of the 
interaction of AAZTA with this trivalent metal ion, in order to evaluate the 
suitability of the corresponding chelate as a PET tracer. 
 
Figure X.1 AAZTA, lipophilic and bifunctional derivatives are reported. 
 
Results and discussion 
 
The thermodynamic and kinetic properties required to a chelating agent to be 




follows: i) high thermodynamic stability; ii) fast kinetic of complex formation; iii) 




The thermodynamic stability of the interaction between Sc
3+
 and AAZTA was 
assessed by a combination of analytical techniques. The formation of the 
Sc(AAZTA)
-





operating in acidic conditions in order to reproduce the classical conditions of 
nuclear medicine (the radiometal is usually eluted from an ion exchange column 
and obtained as acidic eluate). The sequences of spectra registered for the system 
Sc
3+
-AAZTA at different pH are reported in Figure X.2 (
1














]=0.03 – 1.0 M, [H
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The formation of the Sc(AAZTA)
-
 complex is clearly observed to occur, even in 
strongly acidic conditions. Signals of the chelate are detected starting from pH = 0 
and regularly increasing with the pH. The formation of the complex is complete at 
the concentration of [H
+
] 0.03M, showing the strong affinity of the metal ion for 
the coordination environment of AAZTA. 
The plot of the relative concentration of the solution species (i.e.: the aquo-ion, the 
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Scheme X.1. Species distribution of Sc
3+
-AAZTA system and the amount of the 
Sc
3+











]=0.1 M, 25C) 
 
The analysis of these data allows to extract the stability constant for the formation 
of the Sc(AAZTA)
-
 complex logKScL=27.69(4), and its protonation constant 
logKScHL=0.86(3). This value locates between the values recently reported for the 
Sc
3+
 complexes of the archetypal acyclic DTPA and macrocyclic DOTA ligands 
and well above the value reported for EDTA,
[25]
 confirming the strong affinity of 




The determination of the kinetic parameters for the dissociation of the Sc(AAZTA)
-
 
complex had to be adapted to the significant inertness of the chelate, once formed. 
The study of the kinetic stability of Sc(AAZTA)
-
 started with the kinetic studies of 




in the presence of 




Eq. X.1            Sc(AAZTA)
-
  +  Cu(Cit)H-1    Cu(AAZTA)
2-
 + Sc(Cit)H-1     
 
In the pH range 5–7, the citrate prevents the hydrolysis of the exchangeing Cu
2+
 
and the released Sc
3+
 ions. Cu(Cit)H-1 and Sc(Cit)H-1 species predominates in this 
pH range.
[26] 
Some characteristical absorption spectra of the reacting system show 
below Figure X.4. 
 
Figure X.4. UV spectra of Sc(AAZTA) –Cu
2+
-Cit reacting system ([ScL]=0.01 M, 
[CuL]=0.2 mM, [Cu
2+















 is initially assumed to follow a first-order rate law 
(Eq. X.2), where kd and [ScL]t are the pseudo-first-order rate constant and the total 




















During the progress of the transmetallation reactions the concentration of 
Cu(AAZTA)
2-
 complex increases, while that of Cu(Cit)H-1 decreases. By the use of 
1.0 cm cells, the first-order rate constant, kd can be expressed as it follows (Eq. 
X.3): 
 
               Eq. X.3    
 
In Eq. X.3 the Abs/t values (the increase of the absorbance during the time  t) 
were calculated from the slope of the kinetic curves. Cu(Cit)H-1 and CuL are the 
















 in the presence of citrate are shown in Figure 
X.4. 





 in the presence of citrate excess. ([Sc(AAZTA)
-
] = 10.0 mM, [Cu
2+
]=0.2 mM 

































Since the reaction rate (kd) is independent from the concentration of citrate and 
Cu(Cit)H-1, it can be assumed that the rate determining step is the dissociation of 
Sc(AAZTA)
-
, followed by a fast metal exchange reaction between Cu(Cit)H-1 
species and the free AAZTA ligand. The dissociation of the Sc(AAZTA)
- 
might 
take place in a spontaneous pathway characterized with the rate constant k0. The 
increase of kd values with the increase of [H
+
] can be explained by the proton 




Eq. X.4   Sc(AAZTA)
-
                Sc
3+
 + HxAAZTA 
 




                 Sc
3+
 + HxAAZTA 
 
 
                   Eq. X.6 
 
 
Considering the total concentration of the complex ([ScL]tot = [ScL]), the pseudo-
first-order rate constant (kd) can be expressed as follows: 
 




The rate constants characterising the transmetallation reaction of Sc(AAZTA)
-
 in 
the presence of citrate were calculated by fitting the kd values presented in Figure 
X.4 into Eq. X.7 and the values obtained are shown and compared with those of 
Gd(AAZTA)
-


























Table X.1 Rate, equilibrium constants and half-lives (t1/2=ln2/kd) for the 












k  (2  2)10-11  
)sM( 11
1









t1/2 (h) at 




In this work we report a systematic evaluation of AAZTA as a potential chelating 
agent for the development of Sc-radiopharmaceuticals. The fast formation kinetics 
of Sc(AAZTA)
-
 compares favourably with the slow complexation associated with 
macrocyclic derivatives exemplified by DOTA. The thermodynamic formation 
constant of Sc(AAZTA)
-
 demonstrates the substantial stability of this complex, 
higher than those of corresponding acyclic ligands EDTA and DTPA, suggesting a 
significant contribution of the mesocyclic structure of AAZTA. The dissociation of 
Sc(AAZTA)
-
 takes place through an acid catalysed mechanism, with a striking 
kinetic inertness exemplified by a half-life of over two thousand days (~ 5.5 years) 
at physiological pH. 
The combination of the fast kinetics of complex formation, high thermodynamic 
stability and very slow kinetics of dissociation make AAZTA as one of the most 
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Abstract 
Perimidines are extensively studied for their different therapeutic properties, 
including antiulcer, antifungal, antimicrobial, immunosuppressive and anticancer 
activity. Moreover, their heterocyclic structure embodies the naphthalene moiety, 
exploited in bio-imaging and biomolecules staining due to its high fluorescence. 
Although the concomitance of both biologically active moieties and a chromophore 
in the same molecule virtually discloses applications in state-of-art theranostics 
protocols, this aspect of the (photo)chemistry of this otherwise widely studied class 
of compounds were extensively investigated so far. In this work we present the 
spectroscopic characterization of a family of perimidine derivatives, in order to 
obtain useful information potentially useful for the design of compounds 






Keywords: perimidines; fluorescence; intra-tissue drug localization, theranostics 
 
Introduction 
Perimidines are diazaheterotricyclic compounds extensively studied for their 
versatile chemical properties as well as their intense and heterogeneous biological 
activities.
[1]












 a particular interest is assumed by the established 
chemotherapeutic, anti-cancer and anti-proliferative properties of perimidine 
derivatives,
[8,9]
 connected to their DNA-binding properties.
[10]
 Perimidine belongs 
to the class of DNA-targeting antitumor drugs intercalating to DNA, including also 
several pharmaceutical compounds widely used in current medical practice, such as 
anthracyclines, actinomycins, amsacrine, and mitoxantrone. A significant 
correlation has been demonstrated for intercalating agents between in vitro 
cytotoxic potency on one side and both binding affinity and fast binding kinetics on 
the other. Extensive efforts were devoted since the 80’s towards the synthesis of 
compounds maximizing these aspects of the interaction with DNA. These studies 
have shown how planar polycyclic aromatic compounds optimally intercalate and 
that the binding affinity is enhanced by higher nuclearity. However, at the same 
pace as our knowledge of the molecular basis of chemotherapy progressed, a 
growing consciousness matured that maximization of in vitro cytotoxicity, 
although being an important aspect, is not the main design goal for an effective 
anticancer drug substance. Namely, the fundamental properties to be sought are 
broad-spectrum activity, reduced induction of resistance and the ability of reaching 
remotely sited solid tumours. While the former two virtues are assured by drugs 
endowed with the ability of inducing cell death through several diverse pathways, 
which might be triggered by the co-existence of multiple different DNA-binding 




favoured by a low binding constant, since a higher proportion of free ligand will be 
delivered at the systemic level in such instance.
 
Perimidine has a very peculiar interaction with DNA in that its structure has been 
identified as very close to that ideally bearing the minimal features indispensable 
for base intercalation.
[10]
 For this reason, the binding affinity of perimidine for 






). Moreover, its 
binding mode is liable to be more easily shifted, and its binding parameters more 
effectively tuned, by acting on the substituents of the heterotricyclic system. 
Historically, compounds substituted at either nitrogen 1 or carbon 2 position have 
been experimented, but the former were proven not to intercalate to DNA (although 
conserving fairly high binding constants), thereby loosing most of their cytotoxic 
potential.
[10-11]
 2-Substituted perimidines are most straightforwardly synthesized 
from 1,8-diaminonaphthalene and a large number of derivatives thereof were 
evaluated as to their physico-chemical properties, DNA binding affinity and 
cytotoxicity
[9-10]
. Although most of them exhibit DNA-binding constants 
comparable to that of the parent compound, retaining to variable extents an 
intercalative character (evidenced by the capacity of unwinding supercoiled 
plasmid DNA, and quantifiable through the pertaining unwinding angles), and 
induce cell death in vitro with IC50 values in the M range, only a few selected 
derivatives are effective in vivo. The propensity of these compounds to oxidative 
degradation, pivoted by the highly -excessive nature of the naphthalene moiety, 
was suggested as the cause of in vivo inefficacy
[10]
. However, this explanation is 
not consistent with the high cytotoxicity of virtually all the tested compounds in 
vitro, where oxidation should also take place. Moreover, -excessive nature, and 
thus tendency to oxidation, is a feature common also to unsubstituted perimidine 
and to the substituted compounds displaying anti-proliferative properties in mice. 
To this regard, it is worth to mention that cyclic substituents (e.g. aryl rings) appear 




the in vivo effectiveness of perimidine derivatives might be linked to the 
differential capacity of penetrating cell membranes (cell uptake), as well as to 
localize within different cell compartments (e.g. mitochondrial instead of nuclear 
DNA) or to react with alternative intracellular targets (e.g. RNA). Indeed, while in 
vitro the latter features should barely result in modulations of the IC50 value, in vivo 
they are liable to severely modify the systemic distribution.  
From the above discussion it is clear that our comprehension of the molecular 
mechanisms underlying to the perimidines-DNA interactions on the one side and of 
the cellular uptake, bioavailability and bio-distribution at the cellular and systemic 
level on the other side remain still elusive. 
Spectrophotometric titration has been widely and successfully applied to 
elucidation of the binding specificities of small polycyclic ligands to DNA. The 
main requirement preliminary to implementation of this technique is an absorption 
band spectrally separated from that of DNA bases (which is peaked at 260 nm). 
The UV-Vis absorption spectra of several perimidines have been reported in the 




Fluorescence is an even more sensitive tool in order to perform binding studies
[13]
. 




excitation which allow non-invasive acquisition of maps of 
the intracellular and intra-tissue distribution of fluorescent compounds endowed 
with few tens of nanometers resolution as well as quantitative assessments of their 
local concentration and binding status. Because their molecular structure 
encompasses a notably performing fluorophore, 1,8-diaminonaphthalene, whose 
tabulated fluorescence quantum yield is ≈0.2, slightly depending on the 
environment
[15,16]
, perimidines might in principle lend themselves to such analysis. 
In spite of this, the fluorescence properties of perimidine analogues have been so 
far scarcely investigated. The fluorescence quantum yield of these compounds 




dependent. While the latter feature might be promising of large fluorescence 
differences from the free to the bound state in titration experiments, the loss in 
quantum yield with respect to the isolated fluorophore might arise from 
perturbation of the naphthalene charge distribution. Indeed, it has been ascertained 
that the lone-pair of the pyrrole-like nitrogen of the perimidine moiety participates 
to the -system through an electronic-charge transfer from the heterocyclic ring to 
the naphthalene
[9,12]
. Actually, saturation of the heterocyclic ring bonds has been 
reported to induce an increment in fluorescence quantum yield.
[17]
 However, the 
proclivity to act as both a -excessive and a -deficient system, which would be 




In this work we studied a family of perimidines, with the aim of selecting model 
compounds conserving the DNA-binding features of perimidine and suitable for 
spectrophotometric/spectrofluorimetric binding assays and/or fluorescence 
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A total of six perimidines (Figure 1) containing (het)aromatic 2-substituents (in 
addition to the parent unsubstituted 1H-perimidine) were synthesized according to 
previously published procedures or synthesized ex novo. Their UV-Vis absorption 
and fluorescence emission properties were studied in a panel of organic solvents 
differing in polarity and H-bonding affinity, and compared to those of the parent 




physiological environment (phosphate buffered saline), assessed their DNA-
binding affinity by means of spectrophotometric assay and preliminary tested the 
sensitivity of their fluorescence emission to the presence of excess calf thymus 
DNA.  
 
Materials and methods 
 
General 
All chemicals of the highest purity grade were purchased from Sigma-Aldrich, Alfa 




C-NMR were recorded on a JEOL Eclipse ECP 300 operating at 7.05 T. 
Chemical shifts were reported relative to tetramethylsilane (TMS) and were 
referenced by using the residual proton resonances of the solvent. Melting points 
were obtained with a Stuart Scientific SMP3 apparatus and are uncorrected. 
 
Chemistry 
The parent unsubstituted 1H-perimidine was prepared from the condensation of 
1,8-naphthalenediamine with formic acid, according to a reported procedure.
[18]
 All 
the other compounds were prepared in a two-step procedure (Scheme 1) starting 
with the condensation of 1,8-naphthalenediamine with the suitable aldehyde to give 
2-(het)aryl-2,3-dihydro-1H-perimidines, usually isolated by simple filtration from 
the reaction mixture. Following oxidative dehydrogenation
[19]
 to the desired 2-





















General procedure for the synthesis of 2-substituted 2,3-dihydro-1H-
perimidines: 1,8-Diaminonaphthalene (1.0 mmol) and the appropriate aromatic 
aldehyde (1.0 mmol) were sequentially  dissolved in dichloromethane (10 mL) and 
stirred at room temperature. A solid started to separate after 10-15 minutes. The 
reaction mixture was stirred for ≈1h to ensure complete precipitation. The product 
was filtered and washed with dichloromethane, affording the 2-substituted 2,3-
dihydro-1H-perimidine as a light coloured solid. These products were used for the 
next step without any further purification. 
 
2-(2-Pyridyl)-2,3-dihydro-1H-perimidine: 26%; light brown solid; 
1
H-NMR 
(CDCl3, 300MHz, 298K) δ: 8.60 (dt, 1H, Jd=4.6Hz, Jt=0.6Hz), 7.68 (td, 1H, 
Jt=7.7Hz, Jd=1.8Hz), 7.59 (d, 1H, J=7.4Hz), 7.32-7.19 (m, 5H), 6.59 (dd, 2H, 
J=6.7, 1.5Hz), 5.58 (s, 1H), 5.30 (s, 1H, exch. with D2O); 
13
C-NMR (CDCl3, 
75.4MHz, 298K) δ: 159.4 (C), 149.4 (CH), 141.1 (C), 137.4 (CH), 134.8 (C), 127.0 
(CH), 123.7 (CH), 120.9 (CH), 118.2 (CH), 114.1 (C), 106.8 (CH), 67.8 (CH); m.p. 
= 113-114°C. 
2-(2-Pyrrolyl)-2,3-dihydro-1H-perimidine: 74%; light grey solid; 
1
H-NMR 
(DMSO-d6, 300MHz, 298K) δ: 11.08 (bs, 1H, exch. with D2O), 7.15 (t, 2H, 
J=7.8Hz), 6.98 (d, 2H, J=8.0Hz), 6.80-6.74 (m, 1H), 6.65 (s, 2H, exch. with D2O), 
6.51 (d, 2H, J=7.4Hz), 6.19 (bs, 1H), 6.02 (bq, 1H), 5.43 (s, 1H); 
13
C-NMR 




(CH), 115.8 (CH), 113.3 (C), 107.46 (CH), 107.45 (CH), 104.9 (CH), 61.5 (CH); 
m.p. = 195-196°C. 
2-(2-Hydroxy-1-phenyl)-2,3-dihydro-1H-perimidine: 68%; light grey powder; 
1
H-
NMR (CD3OD, 300MHz, 333K) δ: 9.55 (bs, 1H, exch. with D2O), 7.48 (dd, 1H, 
J=7.7, 1.8Hz), 7.20 (td, 1H, Jt=7.6Hz, Jd=1.8Hz), 7.18 (t, 2H, J=7.8Hz), 7.03 (d, 
2H, J=7.8Hz), 6.92 (dd, 1H, J=8.3, 0.9Hz), 6.85 (td, 1H, Jt=7.3Hz, Jd=0.9Hz), 6.58 
(dd, 2H, J=7.4, 0.9Hz), 6.44 (bs, 2H, exch. with D2O), 5.71 (s, 1H); 
13
C-NMR 
(CD3OD, 75.4MHz, 333K) δ: 156.1 (C), 143.6 (C), 135.0 (C), 129.6 (CH), 128.9 
(CH), 127.8 (C), 127.4 (CH), 119.5 (CH), 116.2 (CH), 116.1 (CH), 113.2 (C), 
105.3 (CH), 62.0 (C);  m.p. = 198-199°C. 
2-(2-Hydroxy-1-naphthyl)-2,3-dihydro-1H-perimidine: 50%; light brown powder; 
1
H-NMR (CDCl3, 300MHz, 323K) δ: 9.68 (bs, 1H, exch. with D2O), 7.93 (d, 1H, 
J=8.6Hz), 7.80 (d, 2H, J=8.6Hz), 7.43 (t, 1H, J=7.7Hz), 7.38-7.26 (m, 5H), 7.20 (d, 
1H, J=8.9Hz), 6.60 (d, 2H, J=6.8Hz), 6.42 (s, 1H), 4.66 (bs, 2H, exchanged with 
D2O); 
13
C-NMR (CDCl3, 75.4MHz, 323K) δ: 156.9 (C), 141.5 (C), 135.0 (C), 
132.3 (C), 131.8 (CH), 129.1 (CH), 128.7 (C), 127.4 (CH), 126.9 (CH), 123.3 
(CH), 120.5 (CH), 119.9 (CH), 119.4 (CH), 114.4 (C), 112.8 (C), 107.7 (CH), 63.8 
(CH); m.p. = 172-173°C. 
2-(1-Pyrenyl)-2,3-dihydro-1H-perimidine: 67%; light yellow powder; 
1
H-NMR 
(DMSO-d6, 300MHz, 298K) δ: 8.95 (d, 1H, J=9.2Hz), 8.50-8.14 (m, 7H), 8.07 (t, 
1H, J=7.3Hz), 7.21 (t, 2H, J=7.5Hz), 7.07 (d, 2H, J=8.0Hz), 7.01 (s, 2H, exch. with 
D2O), 6.57 (d, 2H, J=7.0Hz), 6.31 (s, 1H); 
13
C-NMR (DMSO-d6, 75.4MHz, 323K) 
δ: 144.2 (C), 135.2 (C), 134.6 (C), 131.7 (C), 131.4 (C), 130.9 (C), 129.6 (C), 
128.3 (CH), 127.9 (CH), 127.7 (CH), 127.6 (CH), 127.4 (CH), 126.8 (CH), 125.9 
(CH), 125.8 (CH), 125.3 (CH), 125.0 (CH), 124.9 (C), 124.7 (C), 116.2 (CH), 






General procedure for the synthesis of 2-substituted-1H-perimidines: 2-
Substituted 2,3-dihydro-1H-perimidine (1.0 mmol) was dissolved in hot ethanol. 
For some substrates few drops of N,N’-dimethylformamide were added to 
completely dissolve the reagent. Sodium metabisulfite (1.0 mmol) was added in 
one portion at room temperature under vigorous stirring. A solid product started to 
separate after 10-15 minutes. The reaction mixture was stirred overnight, then the 
product was filtered and sequentially washed with cold ethanol and water to give 2-
substituted-1H-perimidine as coloured powders. 
 
2-(2-Pyridyl)-1H-perimidine: 76%; red powder; 
1
H-NMR (DMSO-d6, 300MHz, 
298K) δ: 10.95 (s, 1H, exch. with D2O), 8.73 (dq, 1H, Jd=4.6Hz, Jq=0.8Hz), 8.30 
(dt, 1H, Jd=8.0Hz, Jt=1.1Hz), 8.01 (td, 1H, Jt=7.7Hz, Jd=1.6Hz), 7.62 (ddd, 1H, 
J=7.5, 4.7, 1.2Hz), 7.19 (t, 1H, J=7.7Hz), 7.16 (t, 1H, J=7.1Hz), 7.09 (t, 2H, 
J=7.2Hz), 7.01 (dd, 1H, J=8.3, 0.9Hz), 6.78 (dd, 1H, J=7.4, 0.9Hz), 6.72 (dd, 1H, 
J=7.4, 0.9Hz); 
13
C-NMR (DMSO-d6, 75.4MHz, 298K) δ: 151.4 (C), 149.9 (C), 
149.0 (CH), 145.4 (C), 138.6 (C), 138.1 (CH), 135.7 (C), 129.4 (CH), 128.7 (CH), 
126.7 (CH), 122.9 (C), 122.2 (CH), 120.4 (CH), 118.3 (CH), 114.7 (CH), 104.1 
(CH); m.p. = 175-176°C. 
2-(2-Hydroxy-1-phenyl)-1H-perimidine: 92%; yellow powder; 
1
H-NMR (DMSO-
d6, 300MHz, 298K) δ: 10.66 (bs, 1H, exch. with D2O), 7.98 (dd, 1H, J=8.4, 1.4Hz), 
7.42 (td, 1H, Jt=7.7Hz, Jd=1.4Hz), 7.20 (t, 2H, J=7.8Hz), 7.12 (d, 2H, J=8.0Hz), 
6.95 (t, 1H, J=7.5Hz), 6.94 (d, 1H, J=8.0Hz), 6.70 (dd, 2H, J=7.4, 0.9Hz); 
13
C-
NMR (DMSO-d6, 75.4MHz, 298K) δ: 161.7 (C), 155.3 (C), 139.5 (C), 135.4 (C), 
133.9 (CH), 129.1 (CH), 126.8 (CH), 121.6 (C), 119.9 (CH), 118.6 (CH), 113.4 
(C), 109.5 (bs, CH); m.p. = 266-267°C. 
2-(2-Pyrrolyl)-1H-perimidine: 86%; yellow powder; 
1
H-NMR (DMSO-d6, 
300MHz, 298K) δ: 12.46 (bs, 1H, exch. with D2O), 7.64 (bs, 1H, exchanged with 
D2O), 7.30-7.13 (m, 6H), 7.02-6.88 (m, 2H), 6.31 (bs, 1H). 
13




147.0 (C), 135.2 (C), 134.7 (C), 128.8 (CH), 127.5 (CH), 121.0 (CH), 119.7 (CH); 
118.8 (C), 111.5 (CH), 108.1 (CH). 
2-(1-Pyrenyl)-1H-perimidine: 90%; orange powder; 
1
H-NMR (DMSO-d6, 
300MHz, 298K) δ: 11.08 (s, 1H, exch. with D2O), 8.61 (d, 1H, J=9.2Hz), 8.45-8.24 
(m, 7H), 8.14 (t, 1H, J=7.7Hz), 7.23 (t, 1H, J=7.7Hz), 7.18-7.04 (m, 3H), 6.72 (d, 
1H, J=7.4Hz), 6.43 (d, 1H, J=7.1Hz); 
13
C-NMR (DMSO-d6, 75.4MHz, 323K) δ: 
155.2 (C), 135.9 (C), 132.4 (C), 131.4 (C), 130.9 (C), 130.5 (C), 129.0 (CH), 128.9 
(CH), 127.8 (CH), 127.2 (CH), 126.7 (CH), 126.5 (CH), 126.3 (CH), 125.2 (CH), 
125.0 (CH), 124.5 (C), 124.3 (C), 122.3 (C); m.p. = 292-293°C. 
2-(2-Hydroxy-1-naphthyl)-1H-perimidine: 79%; yellow powder; 
1
H-NMR (DMSO-
d6, 300MHz, 298K) δ: 10.55 (bs, 1H, exch. with D2O), 7.93-7.82 (m, 3H), 7.48 (t, 
1H, J=7.7Hz), 7.34 (t, 1H, J=7.3Hz), 7.27 (d, 1H, J=8.9Hz), 7.14 (t, 2H, J=7.2Hz), 
7.05 (d, 2H, J=8.3Hz), 6.44 (d, 2H, J=7.4Hz); 
13
C-NMR (DMSO-d6, 75.4MHz, 
298K) δ: 153.7 (C), 153.1 (C), 142.8 (C), 135.9 (C), 132.8 (C), 131.2 (CH), 128.9 
(CH), 128.5 (CH), 128.1 (C), 127.5 (CH), 124.1 (CH), 123.5 (CH), 122.4 (C), 
118.9 (CH), 118.8 (CH), 115.7 (C), 108.2 (bs, CH); m.p. = 197-198°C. 
 
Spectroscopic characterization 
The UV-VIS absorption spectra were measured by a Perkin Elmer Lambda 2 
UV-VIS spectrophotometer. For each compound, stock solutions in HPLC-grade 
toluene, acetonitrile (ACN), dimethylsulfoxyde (DMSO) and methanol (MeOH) of 
1mM concentrations were prepared by weighing the powders previously desiccated 
overnight under vacuum. Three more solutions for each sample were prepared by 
dilution of the stocks, their absorption spectra in the 270 nm - 650 nm range were 
acquired and the molar extinction coefficients at the main absorption peak were 
evaluated by linear regression of the absorbance vs concentration plots. The 
fluorescence emission spectra were acquired with a PTI Fluorescence Master 
System spectrofluorimeter. The acquisition software provided on-line correction 




quantum yields were determined by comparison with a solution of dimethyl-
POPOP in cyclohexane (Fl=0.93)
[20]
, excited at the 343 nm absorption peak, by 
normalizing with respect to the relative absorption and solvent refractive index. 
Due to the relatively low quantum yield of some of the compounds, careful 
correction for the solvent signal was necessary. The latter was performed by 
exploiting a home-written Matlab routine: the fluorescence signal was first 
corrected for the absorbance of the sample at the emission spectra wavelengths, 
considering the absorption due to an average optical path of the fluorescence light 
of 5 mm inside the cuvette (whose optical path is 10 mm), then the background 
signal measured on the solvent was subtracted and a smoothing with the Savitzki-
Golay algorithm was performed. 
 
Results and discussion 
 
Spectroscopic characterization in organic solvents.  
The UV-Vis absorption spectra of 1-6 were recorded in the non-polar solvent 
toluene (TOL), in the polar, weakly hydrogen-bonding solvent acetonitrile (ACN), 
in the strongly hydrogen-bonds acceptor dimethylsulfoxide (DMSO) and in the 
protic solvent methanol (MeOH) in the band 270 nm-650 nm. In the most 
transparent solvents, i.e., ACN and MeOH, absorption was measured also in the 
UVB band between 200 nm-270 nm, whereas in the remaining two solvents such 
measurement was prevented due to high solvent absorbance. In ACN and MeOH 
the absorption band peaked at ≈235 nm that was previously observed for several 
perimidine derivatives and attributed to excitation from the bonding 2 
configuration to the corresponding antibonding orbital, 3
*
, within the naphthalene 
system 
[20]
, was punctually detected for all the compounds. However, because this 
band, besides being not easily measurable in some of the selected benchmark 
solvents, corresponds to a local electronic transition and is thus liable of being less 




In this spectral region, the peak around 340 nm falls, which was also early reported 
for several perimidine derivatives and attributed to intramolecular charge transfer 
of the excess electron back from the naphthalene system to the perimidine moiety 
(see introduction). In inert environment (e.g., TOL), such band is expected to be the 
more red-shifted and intense the more mobile and prone to be withdrawn from the 
naphthalene system is the electron. Interaction with solvent molecules of the 
perimidine moiety can either enhance or inhibit the electron withdrawing character 
of such moiety. We note that the removal of the excess electronic charge donated 
by the perimidine heterocycle from the naphthalene system would restore the 
original aromatic character of the fluorophore, hopefully leading to the recovery of 
fluorescence.  
 
Table 1: Spectroscopic properties of compounds 1-6 in organic solvents.     : 
absorption peak wavelength;  : molar extinction coefficient;      : fluorescence 
peak wavelength (--: no detectable fluorescence signal);  : fluorescence quantum 
yield. 
 
Compound Solvent                                   
  
1 ACN 
329 12660 476 0.00126 
 DMSO 
333 22936 482 0.00307 
 MeOH 
329 9480 485 0.00052 
 TOL 
331 12355 472 0.00544 
2 ACN 
341 20860 531 0.0025 
 DMSO 
345 13100 533 0.021 
 MeOH 





342 19300 381 0.036 
3 ACN 
342 18402 400 0.00036 
 DMSO 
345 19197 393 0.00039 
 MeOH 
343 24876 396 0.00030 
 TOL 
343 18955 370 0.00329 
4 ACN 
348 13880 411 0.00026 
 DMSO 
352 16600 --  
 MeOH 
347 19800 400 0.0002 
 TOL 
351 13400 384 0.0077 
5 ACN 
342 31720 --  
 DMSO 
346 30530 --  
 MeOH 
341 28636 406 0.00045 
 TOL 
346 16989 373 0.01604 
6 ACN 
357 15966 --  
 DMSO 
364 16550 477 0.00414 
 MeOH 
334 16143 438 0.00075 
 TOL 
351 17680 382 0.03259 
 
In Table 1 we report the main spectroscopic properties of compounds 1-6 in 
organic solvents. The wavelength of the absorption peak of the charge-transfer 




in the experimental section, are tabulated in the third and fourth column from left, 
respectively . In Fig. 1a) we compare the spectra of the different compounds in 
TOL, while in Fig. 1b) we exemplify the procedure used to determine the 
extinction coefficient values by showing the plots of absorbance as a function of 
concentration obtained for 1 in the different solvents, and the pertaining linear fits. 
 
Figure 1a) Absorption spectra of compounds 1-6 in TOL. Absorbance is 
normalized for concentration equal to 1 M. 1b) Absorption spectra of compound 1 
in DMSO at various concentrations for the determination of the molar extinction 
coefficient. The grey dotted line is drawn in correspondence to the peak 
wavelength. (Inset) The molar extinction coefficient is determined as the slope of 
the best fit line of the absorbance versus concentration graph. 
Similar plots were built up for compounds 2-6 (data not shown). It can be observed 
that all the 2-substitutions induce a bathochromic shift in the charge transfer band. 
This result agrees with previous finding on compound 3
[21]
 as well as on 2-
phenylperimidine.
[12]
 In the quoted reference, it was interpreted as the effect of 
enhanced electron withdrawal from the naphthalene system, due to charge 
conjugation between such group and the aromatic 2-substituents through the 
perimidine heterocycle. Moreover, in TOL the extinction coefficient values are 
higher than that measured for perimidine, 1, for all compounds with the exception 




dipole moment of the corresponding transition, i.e. to the propensity of the 
molecule to undergo such transition. Due to the peculiar behaviour of 4, charge 
transfer seems thus to be not univocally favoured compared to 1 by addition of 
cyclic 2-substituents. The observation that the extinction coefficient value of 4 is 
very similar to that of unsubstituted perimidine might be explained by the fact that, 
as previously attested by molecular dynamics calculations, the six-membered 
heterocyclic ring of perimidine is a rather poor conductor of electronic charge in 
the ground state.
[20]
 Thus, in order for the excess electronic charge to be exchanged 
between the naphthalene system and the added 2-substituents a fairly high potential 
barrier must likely be overcome. In other words, in order to make the charge 
migration energetically favourable and thus the corresponding transition probable 
notably electron withdrawing substituents are required. Indeed, the polyaromatic 
structure of the 5 2-substituent promises high conjugation, while the superior 
electron withdrawing properties of the 2-hydroxyphenyl substituent of 3 with 
respect to the very similar one exhibited by 4 might be a consequence of the 
formation of a further six-membered quasi-aromatic ring due to intramolecular H-
bonding (IHB) between the hydroxyl group of the hydroxyl-phenyl substituent and 
the unsaturated nitrogen of the perimidine heterocycle. For 6, both polyaromaticity 
of the substituent and IHB formation might play a role. It is worth noting that the 




As testified by the parameters detailed in Table 1, the absorption properties are 
only slightly affected by the solvent properties. There are only a few variations that 
are worth to be commented. First, charge transfer from the naphthalene system to 
the cyclic substituent appears to be sensitive to solute-solvent H-bonding 
interactions for both 1 and 6. Namely, interaction with the pure H-bond acceptor 
DMSO seems to enhance the transition probability, whereas interaction with the H-
bond donating MeOH inhibits the charge flux. For 1, such behaviour is denounced 




respect to the very similar values measured in both non-polar (TOL) and polar 
(ACN) weakly H-bonding environment. The spectra of 1 in all the solvents are 
plotted in Fig. 2a).  
In 6, comparable values of the extinction coefficient suggest that the potential 
barrier is comparable in all the benchmark solvents we tested. However, a 
consistent hypsochromic shift with respect to TOL (17 nm) for the compound 
dissolved in protic environment is the symptom of a significant reduction in 
conjugation. Conversely, in DMSO a comparable (13 nm) bathochromic shift is 
observed, which stems in support of enhanced intramolecular charge mobility. The 
spectra of 6 in all the solvents are plotted in Fig. 2b). The second sizeable 
perturbation of the absorption properties due to environmental changes is the 
increment in extinction coefficient, thus in transition dipole moment, measured for 
5 by effect of increasing the solvent polarity, independent of the H-bonding 
character. The spectra of 5 in all the solvents are plotted in Fig. 2c).  
 




Absorbance is normalized for concentration equal to 1 M. 2b) Absorption spectra 
of compound 5 in ACN, DMSO, MeOH and TOL.Absorbance is normalized for 
concentration equal to 1 M. 2c) absorption spectra of compound 6 in ACN, DMSO, 
MeOH and TOL. Absorbance is normalized for concentration equal to 1 M. 
The spectra of compounds 2, 3, and 4 are provided in Figs. S1a), S1b) and S1c) and 
in Figs. S2a)-S2c) we compare the spectral line-shapes of the different compounds 
in ACN, MeOH, and DMSO, respectively. 
 
Figure S1 a) absorption spectra of compound 2 in ACN, DMSO, MeOH and TOL. 
Absorbance is normalized for concentration equal to 1 M. b) absorption spectra of 
compound 3 in ACN, DMSO, MeOH and TOL. Absorbance is normalized for 
concentration equal to 1 M. c) absorption spectra of compound 4 in ACN, DMSO, 




In the fifth and sixth column of Table 1 we report the fluorescence emission peak 
wavelength and the fluorescence quantum yield values, respectively, of compounds 
1-6 in the different solvents. By comparing the emission properties of perimidine, 
1, with those of its 2-substituted analogues, 2-6, in TOL, a first evidence is 
immediately apparent. As shown in Fig. 3, the spectra of 2-6 are systematically 
blue-shifted by as much as 90-100 nm compared to that of the parent compound.  
 
Figure 3: Fluorescence spectra of compounds 1-6 in TOL. 
 
In this regard, they tend to resemble much more to that of the isolated naphthalene 
fluorophore, peaking at 330 nm in cyclohexane. This observation stems in support 
of the hypothesis that introduction of the cyclic substituents in 2- position capable 
of draining part of the excess electronic charge of the six-membered heterocycle 
out of the naphthalene system has the effect of partially restoring its original 
electronic configuration. According with our assumption that in 1 the fluorescence 
is quenched mainly because of perturbation of the aromatic system of naphthalene 
through donation of an excess electron by the peri-fused six-membered 
heterocycle, an enhanced tendency to expel such an electron in the excited state 
should correlate with a fluorescence increase at least in inert environment, where 




negligible. Indeed, the fluorescence quantum yield in TOL increases by as much as 
roughly 50% from 1 to 4, a compound which exhibits increased intramolecular 
charge conjugation (evidenced by bathochromic shift) but a comparable transition 
probability (similar extinction coefficient). The increase in fluorescence quantum 
yield is even more evident in 2, 5 and 6, three compounds combining large 
bathochromic shifts of the charge-transfer absorption band with high increment in 
the corresponding extinction coefficient. The latter have quantum yields exceeding 
that of 1 by at least a factor of four. However, for 3 we measured a quantum yield 
value comparable, and even somewhat lower than that measured for 1. The 
quantum yield value measured for 3 in TOL is very similar to that reported by other 
authors for the same compound in cyclohexane, a solvent sharing very similar 
polarity and H-bonding properties.
[21]
 In the same reference, the authors 
demonstrate that the hypothesis that the unexpectedly low fluorescence quantum 
yield of 3 can be ascribed to an excited-state proton transfer phenomenon occurring 
between the enol moiety and the unsaturated nitrogen must be ruled out. Indeed, 
the notable decrease in quantum yield observed both by us and the above authors as 
a result of IHB quenching by means of polarity and H-bonding interactions with 
solvent molecules would be hardly compatible with such hypothesis. Thus, it must 
be concluded that, although significant, the enrichment in electronic charge of the 
naphthalene system is not the only mechanism dictating the steep reduction in 
fluorescence emission in perimidines with respect to the isolated fluorophore, and 
that specific features of the 2-substituents are also liable to play substantial and 
hardly predictable roles. 
Interaction with a non-inert environment generally quenches the fluorescence 







Figure S3 a) fluorescence  spectra of compound 1 in ACN, DMSO, MeOH and 
TOL. Spectra are normalized to a peak value of 1. b) Fluorescence  spectra of 
compound 2 in ACN, DMSO, MeOH and TOL. Spectra are normalized to a peak 
value of 1. c) Fluorescence  spectra of compound 3 in ACN, DMSO, MeOH and 
TOL. Spectra are normalized to a peak value of 1. d) Fluorescence  spectra of 
compound 4 in ACN, MeOH and TOL. Spectra are normalized to a peak value of 
1. e) Fluorescence  spectra of compound 5 in MeOH and TOL. Spectra are 
normalized to a peak value of 1. f) Fluorescence  spectra of compound 6 in DMSO, 
MeOH and TOL. Spectra are normalized to a peak value of 1. 
Interestingly (see Table 1 and Fig. S3 a-f), the compounds showing the largest 




with the higher intramolecular charge mobility, i.e. 5 and 6. In any case, however, 
there is no straightforward dependence from the polarity of the solvent, suggesting 
that specific solute-solvent interactions, possibly mediated by intermolecular H-
bonding, are of major importance in tuning the excited-state dynamics. Moreover, 
the effects of such interactions are not univocal in the different compounds, but 
depend from the substituent in position 2 of the perimidine. 
 
Spectroscopic characterization in pseudo-physiological environment. 
We now explore the spectroscopic properties of compounds 1-6 in pseudo-
physiological environment. Their absorption spectra in phosphate buffered saline 
(PBS) at pH 7.4 and 150 mM ionic strength are reported in Fig. 4. 
 
Figure 4: Absorption spectra of compounds 1-6 in PBS. Absorbance is normalized 
for concentration equal to 1 M. 
For the great majority of the compounds, virtually excluding only 3 and 5, the 
features of the absorption spectrum in aqueous environment closely resemble those 
of the spectrum measured in MeOH, consistently with the highly polar, H-bonding 
and protic nature of both solvents.  

















), suggesting that water can react as an H-bond acceptor 
with respect to 1 more effectively than MeOH.  
For 2, which exhibited a markedly red-shifted -
*
 transition band also in organic 
solvents (≈290 nm, see Fig. 2), the -
*
 and charge-transfer bands are only slightly 
broadened, but this is sufficient to make the charge transfer band resemble a bare 
shoulder, and the complex of the two transitions appears as a unique, though 
structured, band. 
Compounds 4 and 6 are only slightly hypochromic in water than in alcohol, 
otherwise producing almost superimposable absorption spectral line-shapes in the 
two solvents. 
At difference, compound 5 exhibits considerably red-shifted and hypochromic 
absorption in aqueous environment than in alcohol. Moreover, the spectrum loses 
its structural features and becomes notably broader. These characteristics suggest 
that in PBS the intramolecular charge transfer mechanism producing the UVA band 
requires less energy and that the electronic charge results more conjugated. Instead, 
the potential barrier to be overcome increases. 
Finally, for compound 3 we assist to a dramatic reduction in the UV absorption 
cross section (the molar extinction coefficient at the charge-transfer band peak 








 in water), 
at the advantage of the spectral features in the visible band around 420 nm, which 
were present but minor in organic solvents. This phenomenon might be a symptom 
of enhanced intramolecular conjugation in aqueous medium. 
Coming to the fluorescence properties, all the compounds emit very deem 
fluorescence in water upon excitation at the peak of the charge-transfer band. This 
feature might be beneficial in view of applications of the compounds as DNA 
stains in fluorescence microscopy, provided that measurable fluorescence is 





Assessment of DNA-binding affinity and sensitivity of fluorescence to the 
binding status. 
 
The DNA-binding affinity of the compounds was probed by means of 
spectrophotometric titrations. First, the absorption spectra of 1-6 in PBS added with 
calf thymus DNA (ligand-to-base pair concentration ratio 1:20) were measured. 
They are represented in Fig. 5, while Figs. S4 a)-f) provide direct comparison of 
the absorption spectra of isoconcentrated (15 M) samples of 1-6, respectively, in 
PBS in the presence (data reproduced from Fig. 5) and absence of excess DNA 




Figure 5: Absorption spectra of compounds 1-6 in PBS in the presence of 300 uM 






Figure S4 a) Absorption spectra of 1 in PBS (blue line) or PBS + 300 uM DNA 
(green  line). Absorbance is normalized for concentration equal to 1 M. b) 
Absorption spectra of 2 in PBS (blue line) or PBS + 300 uM DNA (green  line). 
Absorbance is normalized for concentration equal to 1 M. c) Absorption spectra of 
3 in PBS (blue line) or PBS + 300 uM DNA (green  line). Absorbance is 
normalized for concentration equal to 1 M. d) Absorption spectra of 4 in PBS (blue 
line) or PBS + 300 uM DNA (green  line). Absorbance is normalized for 




300 uM DNA (green  line). Absorbance is normalized for concentration equal to 1 
M. f) Absorption spectra of  6 in PBS (blue line) or PBS + 300 uM DNA (green  
line). Absorbance is normalized for concentration equal to 1 M. 
 
It can be observed that binding to DNA produces significant modifications to the 
absorption spectral features in all cases excluded compound 1. Namely, for 3-6 a 
more or less pronounced hyperchromic effect is detected throughout all the 
absorption range, while in the case of 2 it appears that the charge-transfer band is 
corroborated and the -
*
 transition band depressed in intensity as a consequence 
of binding. 
The sizeable modifications in the 2-substituted perimidine derivatives spectral 
properties upon binding were exploited to perform spectrophotometric binding 
titrations in which the DNA base-pairs concentration was varied in the range 0-300 
M while fixing the ligand concentration to 15 M. Obviously, it was not possible 
to perform spectrophotometric titrations of the binding of 1 to DNA, due to the 
negligible effect of binding on the absorption properties. 
An exemplary plot (obtained with 5 as a ligand) of the value of absorbance at the 
charge transfer band peak as a function of DNA concentration is sketched in Fig. 6.  
 
Figure 6. Titration curve for the 
binding of compound 5 to DNA. Points 
correspond to experimental data, solid 
line corresponds to the best fit line 







This experimental binding isotherm was fitted to the independent binding sites 
model 
[13,22]
, i.e., to the following equation: 
 
               
    
 
       
                  
          
 
         
 (Eq.1). 
 
In Eq.(1) Abs(CDNA) represents the predicted absorbance at the charge transfer 
band peak for a sample in which DNA was added in concentration CDNA, Abs0 
represents the predicted absorbance of a 15 mM solution of 5 in the absence of 
DNA, Kapp is the apparent binding constant for the 5-DNA complex, D is the total 
concentration of 5, either free or bound, i.e., 15 M in our instance and Abs×D is 
the enhancement in absorbance which would be measured if the same 
concentration of 5 were completely DNA-bound. Eq. (1) models an initial 
hyperchromicity due to progressive shift of the chemical equilibrium towards the 
bound complex and a subsequent absorbance saturation corresponding to DNA 
concentrations at which virtually all the ligand molecules are bound. 
In Table 2 we report the Kapp values as estimated by applying the above procedure 








, the value 
for typical intercalators such as ethydium bromide[23] and quinacrine 




at similar salt concentrations. 
[20]
 Moreover, 
addition of more aromatic rings in 2-position (as for 5 and 6) and enhancement of 
conjugation by formation of intramolecular H-bonds (in the case of 3 and 5) 
enhance the DNA-binding affinity. These data agree with the early findings of 
Herbert et al., 
[20]
 and stem in support of their hypothesis that, having perimidine a 
structure very close to that ideally bearing the minimal features indispensable for 
base intercalation, perimidine derivatives are susceptible to effective tuning of 





Table 2: apparent binding constants of compounds 1-6 to DNA. *: Binding 
constant for compound 1 was determined through spectrofluorimetric titration, 
while for compounds 2-6 it was determined via spectrophotometric titration. 
Compound        
    
1              * 
2           
3           
4           
5               
6           
 
Finally, we performed measurements of the fluorescence emission of 1-6 upon 
excitation at the charge transfer band peak in the presence of excess calf thymus 
DNA (ligand-to-base pair concentration ratio 1:20). Unfortunately, only 
compounds 1, 5, and 6 emit detectable fluorescence in the above conditions. The 

















Figure7 a) Fluorescence spectrum of compound 1 in PBS (blue line) or PBS + 300 
uM DNA (yellow line). b) Fluorescence spectrum of compound 5 in PBS (blue 
line) or PBS + 300 uM DNA (yellow line). c) Fluorescence spectrum of compound 
6 in PBS (blue line) or PBS + 300 uM DNA (yellow line). 
The corresponding emission spectra in PBS in the absence of DNA are also 
reproduced. It can be observed that, for all these three compounds, binding to DNA 
results in a roughly three-fold increase in the fluorescence intensity, with no 
relevant modifications in the spectral line-shapes. On the other side, it must be said 
that the fluorescence quantum yield of the three compounds bound to DNA in 
pseudo-physiological environment is too low to allow them be applied as DNA 
stains in fluorescence imaging experiments. 
Nonetheless, the notable fluorescence increase measured for 1 as a consequence of 
binding allowed to assess its DNA-binding affinity by means of spectrofluorimetric 
titration. Practically, an experiment similar to those described above, but in which 
the fluorescence emission spectra were recorded as a function of DNA 




binding isotherm was fitted to a suitably modified equation (XXX), in which the 
values of absorbance were substituted by peak fluorescence intensities, and the 
obtained Kapp value is reported in Table 2. Notably, it is in the middle of the range 
of values obtained for the substituted compounds, suggesting that substitutions can 
lead to both enhancement and depression of the binding affinity. 
 
Conclusions 
Perimidine and five 2-substituents were synthesized according to either previously 
reported or novel procedures, and their electronic state transition spectroscopy 
(namely UV-Vis absorption and fluorescence emission) features were characterized 
at varying the environmental properties. The binding affinity to DNA was also 
determined by means of spectrophotometric or spectrofluorimetric titrations. The 









that the binding properties of perimidines are exceptionally tuneable by means of 
chemical substitutions. However, although some of the derivatives show higher 
fluorescence quantum yields in organic solvents with respect to the parent 
compound, none of them conserves this desirable properties in aqueous 
environment. Thus, the analysed compounds demonstrated to be not optimal for 
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Unprecedented Formation of 2,5-Diaminoquinones from the Reaction of 
Vanillin with Secondary Amines in Aerobic Conditions 
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Introduction 
Vanillin (4-hydroxy-3-methoxybenzaldehyde) is one of the most important 
flavoring compounds used in foods, beverages, perfumes and pharmaceuticals. 
This compound is extracted from orchid of the genus Vanilla 
[1]
. However, being 
the extraction very expensive and covering just a little percentage of the market 
request, synthetic vanillin is nowadays the most used. Vanillin was recognized as 
suitable for food use by FDA since 1977 
[2]
. Additionally, several studies on 





 and anti-oxidant 
[6]
 activities. 
Extensive studies have been devoted to the identification of the compounds formed 
during thermal treatments related to the cooking of aliments like, for example, the 
Maillard reaction of carbohydrates in the presence of biogenic amines, finally 
leading to Amadori products.
[7]
 Even if the annual worldwide production and use of 
vanillin is in excess of 1.5·10
4
 tons, it is surprising that few or no investigations 
have been reported on the possible byproducts that could be formed during the use 




While performing a series of reaction on vanillin, initially addressed to the 
preparation of quinomethides, we observed the nearly exclusive formation of 




of vanillin (1) with excess pyrrolidine (2a) in alcoholic solution at room 
temperature originated an initially complex mixture of coloured compounds 
(detected by TLC), ultimately evolving overnight towards the copious precipitation 
of a brick red precipitate. Isolation of the latter and analytical characterization by 
NMR and ESI-MS spectrometry led to the identification of this product as 2,5-
dipyrrolidino-1,4-benzoquinone (3a). Comparison of the product with a sample 
prepared by an independent procedure
[9]
 confirmed its identity. 
Puzzled by this result, we started a systematic investigation of this curious reaction 
by exploring its versatility towards different amines. Different secondary aliphatic 
amines (2a-e, Scheme 1) were found to react in a similar fashion, leading to the 
isolation of good to excellent yields of the corresponding substituted 2,5-diamino-
1,4-benzoquinones (3a-e). Secondary aromatic amines did not react significantly. 
Primary amines, either aliphatic or aromatic, gave limited yields of “simple” imines 








The experimental conditions were then examined in order to gain additional 
information on the mechanism. Heating the reaction mixture (60°C or reflux) 
accelerated the formation of 2,5-diamino-1,4-benzoquinones. Changing the solvent 
led to different results, mainly driven by the limited solubility of the reagents in 
apolar solvents such as diethyl ether or more polar ones as water. Interestingly, the 
reaction proceeded sluggishly under an inert atmosphere and reached almost 
complete conversion after restoring aerobic conditions, suggesting the direct 
intervention of oxygen in an oxidative step. 
Simple reaction mapping allowed to trace back the quinone skeleton to the 
aromatic ring of vanillin, with the evident exclusion of the carbon atom of the 
aldehyde group. Chromatographic separation performed on the residual mother 
liquor of the reaction originally leading to 3a enabled to separate significant 






On the base of the experimental evidences collected in this preliminary 
investigation, we propose the following mechanism for this reaction (Scheme 2). 
The conversion of vanillin to 2,5-diamino-1,4-benzoquinones starts with the 
dehydrative condensation of the aldehyde with the secondary amine (exemplified 
by pyrrolidine 2a in Scheme 2) to give the intermediate iminium ion 5a, that loses 
a proton to give the pyrrolidinoquinomethide 6a. Structural analogues of 6a were 
either invoked as intermediates in cycloadditions
[10]
 or even isolated.
[11]
 Aerobic 
oxidation of the enamine moiety
[12]
 of the quinomethide takes place through a SET 
mechanism
[9]
 leading to the formation of the dioxetane 7a. The unstable four-
membered ring immediately fragments likely through a retro[2+2] cycloaddition 
generating 2-methoxy-1,4-benzoquinone 8a and the observed byproduct N-
formylpyrrolidine 4a. The quinone 8a may be converted to the final 2,5-diamino-
1,4-benzoquinone 3a through two different and converging pathways, involving 
standard quinone chemistry
[13]
: i) conjugate addition of the secondary amine to give 
a 2-amino-5-methoxyhydroquinone 9a, readily oxidised to the corresponding 1,4-
benzoquinone 10a, finally converted to 3a with an ipso-substitution of the methoxy 
group operated through an addition-elimination mechanism;
[13]
 ii) initial ipso-
substitution of the methoxy group by the nucleophilic secondary amine yielding the 
2-amino-1,4-benzoquinone 11a, followed by addition of another molecule of amine 
to give the intermediate 2,5-diaminohydroquinone 12a, finally oxidised to the 
stable end product 3a. 
Further support to this mechanism came from two additional experiments. 
Treatment of commercially available 8a with a slight excess of pyrrolidine in 
ethanol at room temperature in aerobic conditions overnight gave as expected good 
yields of 3a, confirming its involvement as intermediate in the reaction pathway. 
Additionally, ethylvanillin (3-ethoxy-4-hydroxybenzaldehyde, largely employed in 
virtue of its stronger flavouring note and persistance), gave the same reaction 
products on reaction with amines 2a-e, even if slightly longer reaction times were 




The reaction of vanillin with secondary amines appears to be an efficient 
transformation, taking place in mild conditions and with good to excellent yields. 
Safety concerns may be raised by the possibility of this reaction to take place 
during cooking processes in the hot aerobic environment of baking ovens, with 
foods on which vanillin is usually sprayed as an ethanolic solution. Indeed, we 
observed the formation of 2,5-diprolino-1,4-benzoquinone 3f, from the reaction of 
vanillin with excess proline (taken as a model of biogenic secondary amine), even 
if basic mixed aqueous-ethanolic conditions were needed to solubilize proline and 
low yield were registered.  
Preliminary toxicity tests were undertaken in order to evaluate the potential 
biological effect of 2,5-diamino-1,4-benzoquinone, for which no literature data are 
available except for the 2,5-diaziridino analogues, where cytotoxicity and 
mutagenicity is well documented
[14]
 but clearly related to the presence of the 
strained aziridine heterocyclic three-membered rings rather than to the 
benzoquinone moiety. The first results indicate that even at high concentration 2,5-
diamino-1,4-benzoquinones do not show clear toxic effects, though more detailed 
investigation are needed. 
 
Experimental section 
The appropriate secondary amine (4 eq) was added at room temperature to a stirred 
solution of vanillin (1 eq) in ethanol. The resulting reaction mixture was stirred at 
room temperature, checking periodically by TLC. The precipitate was filtered and 
the residual solvent was removed under reduced pressure. The reaction with L-
proline was carried out using the same procedure, adding potassium carbonate (4 
eq) to the reaction mixture. The same procedures were used to perform the reaction 








In this work we report the observation of an unprecedented reaction of vanillin with 
secondary amines in aerobic conditions, leading to the highly efficient formation of 
2,5-diamino-1,4-benzoquinones. The reaction involves several steps and 
intermediates, as exemplified by the reaction mechanism, proposed on the base of 
literature evidences and suitably designed experiments. The importance of this 
reaction stems resides in the possibility of this transformation to occur more 
frequently than considered until now, due to the large use of vanillin (and 
derivatives thereof, as ethylvanillin) and the occurrence of secondary amines, either 
biogenic or thermally/chemically generated in the experimental conditions 
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The PhD activity was dedicated to a wide range exploration of the chemistry of 
imaging probes. The large number of diagnostic techniques developed in the last 
decades stimulated a vast research activity in the field of imaging probes. Imaging 
probes are useful and sometimes necessary for the acquisition of the diagnostic 
images. The work of the PhD period tackled various aspects of the chemistry of 
imaging probes, spanning from chelating agents for MRI and PET applications, to 
-extended luminescent heterocycles for potential use in Optical Imaging. The 
work on chelating agents was concretized in the design of a novel 
diaminotetracarboxylic ligand, whose coordination ability towards metal ions of 
diagnostic interest and biologically relevant ones was studied. The synthesis, 
involving two simple steps from a commodity chemical, allowed to prepare 
multigram samples of the chelating agents and to perform a systematic study of the 
affinity towards metal ions by means of potentiometric techniques. 
 
Furthermore, a chelating agent originally developed for lanthanoids, was devised 
for possible application to long-lived positron emitting radionuclides, recently 
gaining interest for metabolic multi-day imaging. In detail, thermodynamic and 
kinetic parameters for the interaction of AAZTA (a ligand originally developed on 




), were determined by a combination of 
potentiometric, multinuclear NMR and spectrophotometric techniques. The results 
were striking, with the observation of a noteworthy stability constant that, joined 
with an exceptionally slow dissociation kinetic represent an extremely positive 





The research towards Optical Imaging probes involved the scrutiny of structures 
combining favourable photophysical properties (e.g.: intense luminescence) with 
additional features, useful for biological applications. In this context we choose the 
diazaheterotricyclic nucleus of perimidines in order to prepare and to study selected 
substitutes derivatives. The easy synthetic access to 2-substituted perimidines was 
exploited for the preparation of a total of six members of this heterocyclic family, 
all of them with a substantial fluorescence, modulated by the nature of the different 
substituents. This property and the reported DNA-binding ability of perimidines, 
confirmed in our study, lead to interesting potential development of targeted 
imaging probes based on this heterotricyclic scaffold. 
 
Finally, the research activity devoted to Optical Imaging probes led to a 
serendipitous discovery. While performing synthetic approaches en route to push-
pull quinomethides, we observed the unexpected highly efficient formation of 2,5-
diamino-1,4-benzoquinones from the reaction of vanillin with excess secondary 
amines in aerobic conditions. Puzzled by this unusual observation, a systematic 
study was undertaken in order to elucidate the mechanism and the substrate 
versatility of this reaction. The experiments performed allowed to draw a likely 
hypothesis of the mechanistic pathway, involving a complex multistep sequence. 
The reaction appears to be limited to secondary aliphatic amines and the 
involvement of 2-methoxybenzoquinone as an intermediate was demonstrated. The 
study of this transformation, even if not directly related to the chemistry of Imaging 
probes, was nevertheless worthwhile for its implications in food chemistry, due to 
the large use of vanillin and to the superimposability of the reaction conditions to 
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